SUPPLEMENTARY TABLES

Supplementary table 1: missing data for the study population.

	IBD baseline (n = 130)	IBD week 6 (n = 127)	IBD week 14 (n = 122)	Controls (n = 50)
Age (years)	0 (0%)	—	—	0 (0%)
Gender (female/male)	0 (0%)	—	—	0 (0%)
BMI *(kg/m^2)*	12 (9.2%)	—	—	0 (0%)
Disease duration (years)	0 (0%)	—	—	—
Montreal A (age at diagnosis)	0 (0%)	—	—	—
Montreal L (disease location)	0 (0%)	—	—	—
Montreal L4 (upper GI-involvement)	0 (0%)	—	—	—
Montreal B (disease behavior)	0 (0%)	—	—	—
Montreal p (perianal disease)	0 (0%)	—	—	—
Montreal E (disease extension)	1 (1.6%)*	—	—	—
Montreal S (disease severity)	3 (4.9%)*	—	—	—
History of smoking	12 (9.2%)	—	—	—
Proton-pump inhibitor use	0 (0%)	—	—	50 (100%)
Biliary comorbidities	0 (0%)	—	—	—
Arthritis	0 (0%)	—	—	—
History of colectomy	0 (0%)	—	—	—
History of ileocecal resection	0 (0%)	—	—	—
Aminosalicylates	0 (0%)	—	—	—
Steroids	0 (0%)	—	—	—
Immunomodulators	0 (0%)	—	—	—
Recent iron therapy	0 (0%)	—	—	—
Biological naive	0 (0%)	—	—	—
Radiologic activity	53 (76.8%)*	—	67 (97.1%)*	—
Endoscopic activity	58 (44.6%)	—	112 (86.2%)	—
Mayo score	20 (32.8%)*	—	54 (94.7%)*	—
SES-CD score	45 (65.2%)*	—	63 (96.9%)*	—
HBI	27 (39.1%)*	—	20 (30.8%)	—
SCCAI	41 (67.2%)*	—	31 (54.4%)	—
Hemoglobin *(mmol/L)*	1 (0.8%)	3 (2.4%)	5 (4.1%)	—
MCV *(fL)*	2 (1.5%)	3 (2.4%)	5 (4.1%)	0 (0%)
Iron *(µmol/L)*	1 (0.8%)	2 (1.6%)	3 (2.5%)	0 (0%)
Ferritin *(µg/L)*	0 (0%)	2 (1.6%)	3 (2.5%)	2 (4.0%)
TIBC *(µmol/L)*	1 (0.8%)	2 (1.6%)	3 (2.5%)	2 (4.0%)
Transferrin *(g/L)*	4 (3.1%)	4 (3.1%)	4 (3.3%)	2 (4.0%)
TSAT *(%)*	3 (2.3%)	1 (0.8%)	3 (2.5%)	2 (4.0%)
ESR *(mm/hour)*	3 (2.3%)	6 (4.7%)	4 (3.3%)	50 (100%)
CRP *(mg/L)*	1 (0.8%)	2 (1.6%)	3 (2.5%)	0 (0%)
WBC *(x 10^9/L)*	0 (0%)	2 (1.6%)	3 (2.5%)	0 (0%)
Neutrophils *(x 10^9/L)*	2 (1.5%)	7 (5.5%)	5 (4.1%)	0 (0%)
Platelets *(x 10^9/L)*	2 (1.5%)	3 (2.4%)	5 (4.1%)	0 (0%)
Creatinine *(µmol/L)*	1 (0.8%)	2 (1.6%)	3 (2.5%)	0 (0%)
eGFR *(ml/min x 1.73^2)*	3 (2.3%)	3 (2.4%)	5 (4.1%)	0 (0%)
LDH *(U/L)*	4 (3.1%)	5 (3.9%)	4 (3.3%)	0 (0%)
Albumin *(g/L)*	2 (1.5%)	5 (3.9%)	4 (3.3%)	0 (0%)
FCP *(mg/kg)*	61 (46.9%)	—	84 (64.6%)	—

*Data are presented as proportions n with corresponding percentages (%).. IBD: Inflammatory Bowel Disease, HBI: Harvey-Bradshaw Index, SCCAI: Simple Clinical Colitis Activity Index, SES-CD: Simple Endoscopic Score for Crohn's Disease, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin. *: percentage out of the applicable study subgroup, i.e. either Crohn's disease group or ulcerative colitis group.*

Supplementary table 2. Biomarker detection rates.

Biomarker	LLoD	ULoD	Detection rate (%)	Extrapolated values (%)
Hepcidin *(pg/mL)*	15.60	1000.00	99.67%	1.34%
cFGF-23 *(pmol/L)*	0.00	20.00	98.33%	0.67%
iFGF-23 *(pg/mL)*	0.00	1600.00	100.00%	28.09%
sTfR *(µg/mL)*	0.05	2.00	100.00%	2.68%
IL-1β *(pg/mL)*	0.15	3820.00	50.00%	59.33%
IL-6 *(pg/mL)*	0.33	1980.00	91.33%	13.87%
IL-10 *(pg/mL)*	0.14	3720.00	100.00%	57.67%
IL-22 *(pg/mL)*	0.13	3420.00	100.00%	34.67%
IL-23 *(pg/mL)*	1.40	21600.00	60.00%	54.44%
TNFα *(pg/mL)*	0.51	3650.00	100.00%	13.00%
INF-γ *(pg/mL)*	1.70	17000.00	93.67%	25.27%
EPO *(pg/mL)*	1.80	20000.00	100.00%	0.00%
MIP-3α *(pg/mL)*	1.80	20800.00	94.33%	12.01%
VEGF-A *(pg/mL)*	2.00	4920.00	100.00%	0.00%
R-SH *(uM)*	15.60	1000.00	100.00%	0.00%

LLoD: lower limit of detection; ULoD: upper limit of detection. cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols.

Supplementary table 3. Predictors for iron-deficiency anemia at baseline in patients with IBD.

	IRON-DEFICIENCY ANEMIA			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	0.80 (0.38–1.71)	0.57		
Age	0.97 (0.95–1.00)	0.06		
BMI	0.91 (0.84–0.99)	**< 0.05**		
Inflammation				
Log_2 FCP	1.32 (0.96–1.32)	0.09		
Log_2 ESR	1.28 (0.97–1.69)	0.08		
Log_2 CRP	1.15 (0.94–1.41)	0.17		
Log_2 Leukocytes	0.42 (0.20–0.89)	**< 0.05**		
Log_2 Neutrophils	0.64 (0.36–1.14)	0.13		
Log_2 Platelets	1.38 (0.51–3.72)	0.53		
Log_2 Free thiols	0.14 (0.05–0.46)	**< 0.01**	0.10 (0.03–0.39)	**< 0.01**
Log_2 IL-1β	1.32 (0.95–1.84)	0.10		
Log_2 IL-6	1.30 (0.99–1.72)	0.06		
Log_2 IL-10	1.04 (0.77–1.41)	0.80		
Log_2 IL-22	1.01 (0.76–1.36)	0.92		
Log_2 IL-23	1.44 (1.02–2.03)	**< 0.05**		
Log_2 TNFα	0.94 (0.59–1.50)	0.81		
Log_2 INF-γ	1.05 (0.69–1.30)	0.69		
Iron status				
Log_2 Hepcidin	0.78 (0.63–0.96)	**< 0.05**		
Log_2 Iron	0.55 (0.34–0.91)	**< 0.05**		
Log_2 Ferritin	0.54 (0.38–0.75)	**< 0.001**	0.52 (0.35–0.76)	**< 0.01**
Log_2 Transferrin	1.20 (0.27–5.42)	0.81		
Log_2 TIBC	1.44 (0.34–6.21)	0.62		
Log_2 TSAT	0.54 (0.33–0.88)	**< 0.05**		
Hypoxia and erythropoiesis				
Log_2 EPO	1.95 (1.24–3.07)	**< 0.01**	2.24 (1.31–3.84)	**< 0.01**
Log_2 VEGF-A	0.73 (0.50–1.05)	0.09		
Log_2 MIP-3α	1.25 (0.94–1.67)	0.13		
Log_2 sTfR	1.88 (0.92–3.84)	0.08		
Log_2 sTfR/log Ferritin index	2.33 (1.33–4.08)	**< 0.01**		
Log_2 cFGF 23	1.20 (0.88–1.64)	0.25		
Log_2 iFGF 23	0.94 (0.66–1.35)	0.75		
Log_2 c/iFGF ratio	1.16 (0.91–1.47)	0.24		
Other parameters				
MCV	0.94 (0.88–1.01)	0.07		
Log_2 LDH	0.45 (0.17–1.14)	0.09		
Albumin	0.92 (0.82–1.04)	0.18		

For log_2 transformed variables Odds Ratios (OR) represent the increase or decrease in risk of iron-deficiency anemia if the value of the variable doubles. 95% CI: 95% confidence interval, FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.

Supplementary table 4. Predictors for iron deficiency at baseline in patients with IBD.

	IRON DEFICIENCY			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	2.64 (1.05–6.62)	< **0.05**		
Age	0.96 (0.93–0.99)	< **0.01**	0.94 (0.91–0.99)	< **0.001**
BMI	0.95 (0.88–1.02)	0.18		
Inflammation				
Log_2 FCP	0.88 (0.63–1.23)	0.46		
Log_2 ESR	0.94 (0.70–1.27)	0.70		
Log_2 CRP	0.92 (0.74–1.15)	0.47		
Log_2 Leukocytes	0.49 (0.22–1.10)	0.09		
Log_2 Neutrophils	0.66 (0.34–1.26)	0.21		
Log_2 Platelets	1.57 (0.50–4.92)	0.44		
Log_2 Free thiols	0.45 (0.14–1.40)	0.17		
Log_2 IL-1β	1.00 (0.75–1.33)	0.99		
Log_2 IL-6	0.95 (0.72–1.26)	0.72		
Log_2 IL-10	0.87 (0.62–1.22)	0.43		
Log_2 IL-22	0.93 (0.67–1.29)	0.65		
Log_2 IL-23	0.94 (0.71–1.24)	0.66		
Log_2 TNFα	0.91 (0.54–1.53)	0.72		
Log_2 INF-γ	0.92 (0.71–1.20)	0.53		
Iron status				
Log_2 Hepcidin	0.26 (0.15–0.45)	< **0.001**	0.24 (0.13–0.43)	< **0.001**
Log_2 Iron	0.96 (0.56–1.66)	0.90		
Log_2 Transferrin	16.50 (1.99–136.68)	< **0.01**		
Log_2 TIBC	24.19 (3.08–190.26)	< **0.01**		
Log_2 TSAT	0.72 (0.42–1.25)	0.25		
Hypoxia and erythropoiesis				
Log_2 EPO	1.20 (0.77–1.88)	0.43		
Log_2 VEGF-A	0.73 (0.47–1.12)	0.15		
Log_2 MIP-3α	1.19 (0.87–1.64)	0.28		
Log_2 sTfR	1.62 (0.71–3.73)	0.25		
Log_2 sTfR/log Ferritin index	7.46 (2.83–19.69)	< **0.001**		
Log_2 cFGF	1.16 (0.82–1.64)	0.41		
Log_2 iFGF	0.99 (0.66–1.49)	0.96		
Log_2 c/iFGF ratio	1.09 (0.82–1.44)	0.56		
Other parameters				
Hemoglobin	0.70 [0.42–1.18]	0.18		
MCV	1.004 (0.93–1.08)	0.92		
Log_2 LDH	0.52 (0.20–1.33)	0.17		
Albumin	1.03 (0.91–1.17)	0.65		

For log_2 transformed variables Odds Ratios (OR) represent the increase or decrease in risk of iron deficiency if the value of the variable doubles. 95% CI: 95% confidence interval, FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.

Supplementary table 5. Changes in inflammation and systemic iron parameters during induction therapy with either infliximab or vedolizumab in patients with Crohn's disease.

	Baseline (n = 66)	Week 6 (n = 65)	Week 14 (n = 62)	Δ baseline to week 6	Δ baseline to week 14
Hemoglobin *(mmol/L)*	**7.97 (± 0.83)**	**8.10 [7.43–8.85]**	**8.05 [7.73–8.56]**	***P* < 0.05**	***P* < 0.05**
Hemoglobin females	*7.77 (±0.76)*	*7.70 [7.30–8.50]*	*7.90 [7.63–8.30]*	*P = 0.19*	***P* < 0.05**
Hemoglobin males	*8.30 (± 0.85)*	*8.40 [8.05–9.20]*	*8.50 [8.03–8.88]*	*P = 0.05*	*P = 0.24*
MCV *(fL)*	89.90 [85.23–93.00]	89.70 [86.08–93.25]	90.00 [86.10–92.48]	*P* < 0.05	*P* = 0.54
Ferritin *(µg/L)*	45.50 [23.00–89.25]	36.50 [24.25–69.00]	37.00 [25.50–66.50]	***P* < 0.001**	***P* < 0.05**
Iron *(µmol/L)*	11.00 [7.30–15.70]	13.90 [9.70–19.00]	14.00 [8.10–18.25]	P = 0.06	*P* = 0.08
Transferrin *(g/L)*	2.50 [2.20–2.90]	2.60 [2.30–3.10]	2.65 [2.40–3.00]	***P* < 0.001**	***P* < 0.001**
TIBC *(µmol/L)*	62.00 [55.00–73.00]	65.50 [57.25–77.00]	66.00 [60.00–76.00]	***P* < 0.001**	***P* < 0.001**
TSAT *(%)*	18.00 [12.00–26.75]	20.00 [13.00–28.00]	20.00 [12.50–27.50]	*P* = 0.20	*P* = 0.26
Hepcidin *(ng/mL)*	20.87 [7.98–40.98]	9.05 [2.62–22.27]	*NA*	***P* < 0.001**	*NA*
sTfR *(µg/mL)*	7.39 [5.97–9.74]	7.20 [6.05–8.91]	*NA*	*P* = 0.68	*NA*
sTfR/log Ferritin Index	4.68 [3.50–5.91]	4.62 [3.31–6.30]	*NA*	*P* = 0.27	*NA*
EPO *(pg/mL)*	77.60 [49.83–134.78]	64.78 [45.91–100.94]	*NA*	*P* < 0.05	*NA*
MIP-3α *(pg/mL)*	19.88 [12.68–30.02]	16.50 [9.35–25.64]		***P* < 0.05**	*NA*
VEGF-A *(pg/mL)*	117.96 [77.38–228.22]	113.41 [62.74–172.88]		***P* < 0.05**	*NA*
R-SH *(uM)*	244.88 [209.70–285.21]	241.22 [211.79–299.63]	*NA*	*P* = 0.35	*NA*
ESR *(mm/hour)*	20.00 [9.00–39.00]	12.00 [4.00–25.00]	10.50 [5.00–29.50]	***P* < 0.001**	***P* < 0.01**
CRP *(mg/L)*	5.20 [1.75–12.50]	1.75 [0.90–6.00]	3.00 [0.75–9.50]	***P* < 0.001**	***P* < 0.05**
WBC *(x 10^9/L)*	7.90 [6.08–10.63]	6.60 [5.03–8.00]	6.60 [4.85–9.10]	***P* < 0.001**	***P* < 0.01**
Neutrophils *(x 10^9/L)*	5.14 [3.99–7.59]	4.02 [3.06–5.71]	3.92 [2.76–5.81]	***P* < 0.001**	***P* < 0.001**
Platelets *(x 10^9/L)*	327.00 [255.50–389.50]	287 [244.25–360.50]	300.50 [240.50–343.00]	***P* < 0.01**	***P* < 0.001**
FCP *(mg/kg)*	667.00 [273.25–2290.00]	*NA*	147.50 [81.75–1437.50]	*NA*	*P* = 0.48

*Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, TIBC: total iron-binding capacity, TSAT: transferrin saturation, sTfR: soluble Transferrin Receptor, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, CRP: C-reactive protein, WBC: white blood cell count, FCP: fecal calprotectin, NA: not measured. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 6. Changes in inflammation and systemic iron parameters during induction therapy with either infliximab or vedolizumab in patients with ulcerative colitis.

	Baseline (n = 56)	Week 6 (n = 54)	Week 14 (n = 52)	Δ baseline to week 6	Δ baseline to week 14
Hemoglobin *(mmol/L)*	**8.16 (± 0.90)**	**8.00 [7.70–8.68]**	**8.25 [7.68–8.70]**	*P* = 0.40	*P* = 0.24
Hemoglobin females	*7.70 [7.45–8.15]*	*7.75 [7.38–8.00]*	*7.80 [7.15–8.00]*	*P = 0.32*	*P = 1.00*
Hemoglobin males	*8.40 [7.80–9.13]*	*8.50 [7.90–8.95]*	*8.50 [7.95–9.05]*	*P = 0.09*	*P = 0.13*
MCV *(fL)*	91.60 [87.13–94.58]	90.80 [87.53–94.68]	90.10 [86.68–94.13]	*P* = 0.51	*P* < 0.05
Ferritin *(µg/L)*	45.00 [24.00–96.50]	37.00 [22.50–76.00]	40.00 [22.00–68.00]	***P* < 0.01**	***P* < 0.01**
Iron *(µmol/L)*	13.65 [9.43–18.75]	14.20 [9.40–18.15]	13.10 [7.80–19.60]	*P* = 0.78	*P* = 0.88
Transferrin *(g/L)*	2.40 [2.20–2.60]	2.50 [2.30–2.80]	2.50 [2.30–2.70]	*P* < 0.05	*P* < 0.05
TIBC *(µmol/L)*	60.50 [56.00–66.00]	63.00 [57.50–70.00]	64.00 [58.00–68.00]	*P* < 0.05	*P* < 0.05
TSAT *(%)*	22.00 [15.00–32.00]	23.00 [13.00–29.00]	22.00 [12.00–31.00]	*P* = 0.45	*P* = 0.50
Hepcidin *(ng/mL)*	10.30 [3.31–21.77]	10.67 [3.01–17.69]	*NA*	*P* = 0.20	*NA*
sTfR *(µg/mL)*	7.39 [5.37–10.40]	8.19 [6.26–10.85]	*NA*	*P* = 0.16	*NA*
sTfR/log Ferritin Index	4.50 [3.40–6.78]	4.94 [3.51–7.75]	*NA*	*P* < 0.05	*NA*
EPO *(pg/mL)*	83.63 [58.31–129.92]	92.23 [60.98–151.99]	*NA*	*P* = 0.96	*NA*
MIP-3α *(pg/mL)*	19.67 [10.69–31.40]	18.04 [12.67–27.16]		*P* = 0.39	
VEGF-A *(pg/mL)*	119.61 [77.93–186.98]	109.18 [69.24–190.52]		*P* = 0.49	
R-SH *(uM)*	216.54 [188.78–258.00]	229.74 [187.45–265.95]	*NA*	*P* = 0.25	*NA*
ESR *(mm/hour)*	16.00 [6.00–37.75]	14.00 [7.00–30.00]	12.00 [7.00–21.00]	*P* = 0.07	*P* < 0.05
CRP *(mg/L)*	2.80 [1.13–5.00]	2.20 [0.80–5.00]	1.60 [0.80–6.50]	*P* = 0.12	*P* = 0.12
WBC *(x 10^9/L)*	7.65 [5.73–9.03]	6.30 [5.20–7.30]	6.00 [4.90–7.40]	***P* < 0.001**	***P* < 0.001**
Neutrophils *(x 10^9/L)*	5.11 [3.69–7.64]	4.12 [2.83–4.98]	3.62 [2.90–4.86]	***P* < 0.001**	***P* < 0.001**
Platelets *(x 10^9/L)*	289.00 [239.50–350.25]	266.50 [233.00–316.75]	264.00 [237.25–297.50]	*P* = 0.26	*P* = 0.29
FCP *(mg/kg)*	830.00 [255.00–1650.00]	*NA*	150.00 [41.00–640.00]	*NA*	***P* < 0.001**

*Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, TIBC: total iron-binding capacity, TSAT: transferrin saturation, sTfR: soluble Transferrin Receptor, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, CRP: C-reactive protein, WBC: white blood cell count, FCP: fecal calprotectin, NA: not measured. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 7. Changes in biochemical parameters in patients with IBD undergoing induction therapy with either infliximab or vedolizumab.

	Infliximab baseline (n = 71)	Infliximab week 6 (n = 71)	Paired analysis	Vedolizumab baseline (n = 51)	Vedolizumab week 6 (n = 48)	Paired analysis	Δ difference between biologicals
Hemoglobin ***(mmol/L)***	**7.97 (± 0.82)**	**8.10 [7.38–8.50]**	***P* < 0.05**	**8.18 (± 0.92)**	**8.00 [7.60–8.75]**	*P* = 0.72	*P* = 0.08
Hemoglobin females	*7.72 (± 0.74)*	*7.70 [7.20–8.40]*	*P = 0.54*	*7.70 [7.50–8.30]*	*7.75 [7.48–8.03]*	*P = 0.90*	*P = 0.83*
Hemoglobin males	*8.22 (± 0.83)*	*8.50 [8.00–9.00]*	***P < 0.01***	*8.50 [7.90–9.28]*	*8.50 [7.93–9.35]*	*P = 0.66*	*P < 0.05*
Systemic iron status parameters							
Ferritin *(µg/L)*	46.00 [23.00–102.00]	38.50 [21.00–73.75]	***P* < 0.001**	44.00 [24.00–80.00]	36.00 [23.00–71.00]	*P* < 0.05	*P* = 0.34
Iron *(µmol/L)*	14.00 [8.70–17.25]	14.10 [11.45–19.25]	*P* = 0.11	11.00 [8.10–17.30]	12.20 [8.20–16.70]	*P* = 0.82	*P* = 0.19
Transferrin *(g/L)*	2.40 [2.20–2.80]	2.50 [2.30–3.00]	***P* < 0.001**	2.40 [2.20–2.70]	2.50 [2.30–2.80]	***P* < 0.01**	*P* = 0.84
TIBC *(µmol/L)*	60.50 [55.75–71.00]	63.50 [56.50–75.25]	***P* < 0.001**	61.00 [55.00–67.00]	64.00 [58.00–71.00]	***P* < 0.01**	*P* = 0.92
TSAT *(%)*	21.50 [13.25–28.00]	24.00 [15.00–29.00]	*P* = 0.32	18.00 [13.00–26.00]	19.00 [12.00–28.00]	*P* = 0.52	*P* = 0.23
Hepcidin *(ng/mL)*	13.37 [5.95–40.86]	7.68 [2.29–18.68]	***P* < 0.001**	13.67 [3.93–22.73]	12.09 [5.43–26.11]	*P* = 0.31	*P* = 0.08
sTfR *(µg/mL)*	7.91 [6.00–10.26]	7.16 [6.01–9.11]	*P* < 0.05	7.05 [5.33–9.41]	8.19 [6.68–10.10]	***P* < 0.001**	***P* < 0.001**
sTfR/log ferritin index	4.68 [3.52–6.45]	4.39 [3.43–6.36]	*P* = 0.93	4.51 [3.09–5.84]	5.25 [3.51–7.27]	***P* < 0.01**	***P* < 0.01**
Inflammation-associated parameters							
CRP *(mg/L)*	4.80 [1.85–13.00]	1.55 [0.58–4.70]	***P* < 0.01**	2.60 [1.20–8.00]	2.90 [1.40–7.00]	*P* = 0.84	***P* < 0.001**
ESR *(mm/hour)*	18.00 [9.00–36.75]	11.00 [4.00–21.50]	***P* < 0.01**	17.00 [6.00–43.00]	15.00 [10.00–33.00]	*P* = 0.66	***P* < 0.001**
WBC *(x 10^9/L)*	7.40 [6.00–9.70]	6.30 [4.48–7.80]	***P* < 0.01**	8.00 [5.80–10.80]	6.80 [5.70–8.90]	***P* < 0.01**	*P* = 0.14
Neutrophils *(x 10^9/L)*	5.13 [4.00–7.11]	3.97 [2.60–4.93]	***P* < 0.01**	5.15 [3.68–8.53]	4.31 [3.33–6.03]	***P* < 0.01**	*P* = 0.15
Platelets *(x 10^9/L)*	304.50 [256.25–377.75]	273.00 [240.75–336.75]	***P* < 0.001**	304.50 [237.75–364.25]	288.50 [239.00–349.25]	*P* = 0.83	*P* < 0.05
cFGF-23 *(pmol/L)*	1.03 [0.52–1.59]	0.96 [0.52–1.80]	*P* = 0.23	0.77 [0.40–1.20]	1.03 [0.46–1.48]	*P* = 0.54	*P* = 0.68
iFGF-23 *(pg/mL)*	10.13 [5.93–13.55]	7.96 [5.07–12.24]	*P* = 0.23	10.25 [7.81–14.38]	9.67 [7.92–13.08]	*P* = 0.52	*P* = 0.86
c/iFGF-23 ratio	0.11 [0.05–0.19]	0.11 [0.06–0.23]	*P* = 0.34	0.07 [0.04–0.11]	0.08 [0.04–0.14]	*P* = 0.83	*P* = 0.42
IL-1β *(pg/mL)*	1.24 [1.06–1.36]	1.13 [0.89–1.31]	*P* = 0.05	0.63 [0.12–1.09]	0.91 [0.35–1.34]	*P* = 0.22	*P* < 0.05
IL-6 *(pg/mL)*	2.30 [0.95–3.56]	1.46 [0.77–2.03]	***P* < 0.01**	2.00 [1.08–4.75]	2.26 [1.33–3.77]	*P* = 0.84	*P* = 0.06
IL-10 *(pg/mL)*	1.20 [0.40–1.58]	1.32 [0.44–1.78]	***P* < 0.05**	0.93 [0.56–1.46]	0.87 [0.59–1.55]	*P* = 0.84	*P* = 0.10
IL-22 *(pg/mL)*	1.15 [0.60–1.62]	0.94 [0.53–1.26]	***P* < 0.01**	1.26 [0.84–2.50]	0.96 [0.67–1.62]	*P* < 0.05	*P* = 0.82
IL-23 *(pg/mL)*	7.39 [6.75–8.03]	7.38 [6.64–8.81]	*P* = 0.32	1.13 [0.55–7.84]	1.51 [0.29–7.94]	*P* = 0.95	*P* = 0.27
TNFα *(pg/mL)*	2.08 [1.43–2.61]	1.52 [0.67–2.09]	***P* < 0.001**	2.07 [1.85–3.13]	2.32 [1.93–3.26]	*P* = 0.19	***P* < 0.01**
INF-γ *(pg/mL)*	18.51 [8.66–31.93]	15.32 [6.48–31.10]	*P* = 0.30	16.26 [8.04–29.63]	14.65 [8.91–32.85]	*P* = 0.39	*P* = 0.97
R-SH *(uM)*	238.23 [191.64–278.81]	244.63 [206.05–300.51]	*P* = 0.08	232.35 [196.74–267.23]	223.73 [188.46–265.87]	*P* = 0.87	*P* = 0.33
FCP *(mg/kg)* ‡	957.50 [406.25–2182.50]	120.00 [40.00–300.00]	*P* = 0.35	494.00 [215.00–1530.00]	152.50 [44.25–957.75]	***P* < 0.01**	*P* = 0.40
Hypoxia-associated parameters							
EPO *(pg/mL)*	88.20 [57.52–146.67]	64.78 [45.37–123.97]	***P* < 0.01**	75.94 [52.85–105.30]	82.45 [60.28–114.90]	*P* = 0.19	***P* < 0.01**
MIP-3α *(pg/mL)*	18.60 [10.86–28.48]	15.52 [9.31–21.99]	***P* < 0.01**	22.49 [11.29–33.23]	21.60 [12.24–36.11]	*P* = 0.94	*P* = 0.07
VEGF-A *(pg/mL)*	115.35 [76.84–220.09]	102.48 [56.49–172.19]	***P* < 0.01**	120.56 [83.10–211.16]	119.60 [75.75–212.83]	*P* = 0.98	*P* < 0.05
Other parameters							
MCV *(fL)*	89.95 [85.30–93.08]	90.35 [86.38–93.33]	*P* = 0.12	91.10 [86.95–94.63]	89.85 [87.00–94.88]	*P* = 0.95	*P* = 0.38
LDH *(U/L)*	164.50 [139.75–205.00]	169.00 [141.00–199.75]	*P* = 0.14	176.00 [151.00–225.75]	193.50 [147.75–253.25]	*P* = 0.68	*P* = 0.57
Albumin *(g/L)*	42.00 [40.00–44.00]	42.00 [41.00–44.00]	***P* < 0.05**	41.00 [39.00–43.00]	42.00 [40.00–44.00]	*P* = 0.26	*P* = 0.50

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in ***bold*** *represent statistical significance after adjustment for multiple testing.*

Supplementary table 8. Change in biochemical parameters in patients with IBD, stratified by iron-deficient or iron-sufficient status at baseline.

	ID baseline (n = 95)	ID week 6 (n = 92)	Paired analysis	NON-ID baseline (n = 27)	NON-ID week 6 (n = 27)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**7.90 [7.40–8.50]**	**8.00 [7.50–8.60]**	*P* = 0.13	**8.35 [7.80–8.63]**	**8.50 [8.00–9.00]**	*P* = 0.09	*P* = 0.12
Hemoglobin females	*7.70 [7.28–8.23]*	*7.70 [7.25–8.10]*	*P = 0.61*	*8.40 [7.68–8.50]*	*8.05 [7.50–8.65]*	*P = 0.92*	*P = 0.82*
Hemoglobin males	*8.30 [7.85–9.15]*	*8.40 [7.90–9.18]*	*P = 0.10*	*8.30 [7.80–8.80]*	*8.60 [8.20–9.20]*	*P < 0.05*	*P = 0.17*
Systemic iron status parameters							
Ferritin *(µg/L)*	34.00 [21.00–61.00]	30.50 [18.00–45.00]	***P* < 0.01**	142.00 [115.00–211.00]	102.00 [78.00–165.00]	***P* < 0.001**	***P* < 0.001**
Iron *(µmol/L)*	12.00 [8.38–16.78]	13.30 [8.98–19.00]	*P* = 0.55	15.50 [8.00–19.00]	15.20 [12.00–18.40]	*P* = 0.20	*P* = 0.43
Transferrin *(g/L)*	2.50 [2.20–2.85]	2.60 [2.38–3.10]	***P* < 0.001**	2.30 [2.15–2.50]	2.40 [2.20–2.60]	*P* = 0.07	*P* = 0.14
TIBC *(µmol/L)*	63.00 [56.00–71.50]	66.50 [58.75–77.00]	***P* < 0.001**	57.00 [50.00–61.00]	59.00 [53.00–64.00]	*P* = 0.07	*P* = 0.13
TSAT *(%)*	18.00 [12.25–27.00]	18.00 [13.00–28.00]	*P* = 0.79	22.00 [15.00–31.00]	25.00 [21.00–29.00]	*P* = 0.26	*P* = 0.29
Hepcidin *(ng/mL)*	9.62 [3.80–21.19]	6.23 [1.83–13.24]	***P* < 0.01**	46.15 [23.32–67.68]	27.21 [16.56–54.08]	*P* < 0.05	*P* < 0.05
sTfR *(µg/mL)*	7.36 [5.95–10.21]	7.77 [6.11–10.00]	*P* = 0.65	7.49 [5.67–8.66]	7.24 [6.31–8.21]	*P* = 0.46	*P* = 0.62
sTfR/log Ferritin Index	4.98 [3.65–6.81]	5.31 [3.93–7.39]	*P* = 0.14	3.46 [2.47–4.23]	3.49 [3.04–3.94]	*P* < 0.05	*P* = 0.62
Inflammation-associated parameters							
CRP *(mg/L)*	3.55 [1.60–10.25]	2.10 [0.90–6.00]	***P* < 0.01**	5.00 [1.10–22.00]	1.70 [0.80–5.00]	***P* < 0.01**	*P* = 0.09
ESR *(mm/hour)*	18.00 [9.00–36.75]	13.50 [6.00–28.50]	***P* < 0.001**	17.00 [6.00–43.00]	12.00 [4.00–28.00]	*P* < 0.05	*P* = 0.80
WBC *(x 10^9/L)*	7.30 [5.70–9.40]	6.50 [5.10–7.73]	***P* < 0.001**	8.80 [6.80–10.70]	6.60 [5.30–8.20]	***P* < 0.01**	*P* = 0.14
Neutrophils *(x 10^9/L)*	4.96 [3.69–7.58]	4.01 [2.97–5.07]	***P* < 0.001**	6.49 [4.53–8.24]	4.14 [3.15–5.81]	***P* < 0.001**	*P* = 0.09
Platelets *(x 10^9/L)*	307.00 [256.50–372.25]	279.00 [244.00–333.50]	***P* < 0.01**	266.00 [234.75–368.00]	270.00 [220.00–369.00]	*P* = 0.22	*P* = 0.40
cFGF-23 *(pmol/L)*	0.92 [0.48–1.53]	0.93 [0.49–1.65]	*P* = 0.42	0.83 [0.39–1.37]	1.07 [0.46–1.55]	*P* = 0.25	*P* = 0.48
iFGF-23 *(pg/mL)*	10.32 [7.17–13.45]	9.07 [6.40–12.73]	*P* = 0.15	8.72 [5.66–15.59]	9.39 [5.66–12.49]	*P* = 0.97	*P* = 0.64
c/iFGF-23 ratio	0.10 [0.05–0.17]	0.10 [0.05–0.19]	*P* = 0.76	0.06 [0.04–0.13]	0.10 [0.06–0.15]	*P* = 0.50	*P* = 0.82
IL-1β *(pg/mL)*	1.10 [0.22–1.27]	1.07 [0.72–1.30]	*P* = 0.81	1.14 [0.28–1.35]	1.13 [0.66–1.33]	*P* < 0.05	*P* = 0.10
IL-6 *(pg/mL)*	2.15 [1.01–3.79]	1.61 [1.02–2.89]	*P* < 0.05	2.28 [1.02–4.88]	1.54 [1.03–2.63]	*P* = 0.07	*P* = 0.79
IL-10 *(pg/mL)*	0.96 [0.51–1.56]	1.01 [0.51–1.71]	*P* < 0.05	0.97 [0.40–1.53]	0.88 [0.46–1.74]	*P* = 0.53	*P* = 0.74
IL-22 *(pg/mL)*	1.16 [0.71–1.78]	0.92 [0.55–1.35]	***P* < 0.001**	1.21 [0.91–2.34]	1.19 [0.83–2.36]	*P* = 0.50	*P* = 0.24
IL-23 *(pg/mL)*	6.83 [0.80–7.97]	6.92 [0.93–8.75]	*P* = 0.37	6.80 [0.83–7.88]	7.31 [1.89–8.49]	*P* = 0.59	*P* = 0.57
TNFα *(pg/mL)*	2.07 [1.54–2.80]	1.91 [1.12–2.84]	***P* < 0.05**	2.07 [1.43–3.40]	1.90 [0.74–2.93]	*P* < 0.05	*P* = 0.46
INF-γ *(pg/mL)*	17.29 [7.73–30.42]	13.41 [7.39–27.43]	*P* = 0.06	15.70 [12.14–42.86]	25.86 [15.32–43.43]	*P* = 0.69	*P* = 0.20
R-SH *(uM)*	232.35 [191.31–270.05]	239.79 (SD 58.93)	*P* = 0.07	243.42 [209.54–302.10]	258.14 [197.18–299.67]	*P* = 0.77	*P* = 0.30
FCP *(mg/kg)* ‡	724.50 [255.00–1741.75]	138.00 [41.00–850.00]	***P* < 0.01**	1021.00 [400.00–2130.00]	182.50 [108.75–802.50]	*P* = 0.75	*P* = 0.93
Hypoxia-associated parameters							
EPO *(pg/mL)*	83.38 [54.59–136.51]	82.45 [55.79–129.34]	*P* = 0.32	77.05 [53.50–119.09]	63.37 [44.56–93.97]	*P* = 0.09	*P* = 0.45
MIP-3α *(pg/mL)*	20.68 [12.58–32.17]	18.52 [10.65–27.13]	*P* < 0.05	18.11 [10.54–26.02]	15.11 [10.78–20.25]	*P* = 0.21	*P* = 0.75
VEGF-A *(pg/mL)*	110.39 [77.54–190.13]	101.89 [61.34–153.99]	***P* < 0.01**	162.36 [80.98–300.23]	177.82 [87.06–282.24]	*P* = 0.47	*P* < 0.05
Other parameters							
MCV *(fL)*	90.35 [86.25–93.33]	90.30 [86.20–94.20]	*P* = 0.36	90.45 [85.35–93.90]	90.00 [86.60–93.40]	*P* = 0.61	*P* = 0.79
LDH *(U/L)*	166.50 [140.25–205.75]	168.00 [140.00–215.00]	*P* = 0.15	178.50 [154.00–215.50]	186.00 [168.00–212.00]	*P* = 0.68	*P* = 0.74
Albumin *(g/L)*	42.00 [40.00–43.00]	42.00 [41.00–44.00]	*P* < 0.05	40.00 [38.00–44.00]	42.00 [39.00–44.00]	*P* = 0.20	*P* = 0.79

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. ID: iron deficiency, NON-ID: iron-sufficient status MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in ***bold*** *represent statistical significance after adjustment for multiple testing.*

Supplementary table 9. Change in biochemical parameters in patients with Crohn's disease, stratified by iron-deficient or iron-sufficient status at baseline.

	ID baseline (n = 52)	ID week 6 (n = 51)	Paired analysis	NON-ID baseline (n = 14)	NON-ID week 6 (n = 14)	Paired analysis	Δ difference between groups
Hemoglobin *(mmol/L)*	**7.92 (± 0.82)**	**8.00 [7.40–8.60]**	*P* = 0.08	**8.30 [7.60–8.80]**	**8.55 [7.88–9.23]**	*P* = 0.17	*P* = 0.07
Hemoglobin females	*7.70 (± 0.74)*	*7.70 [7.28–8.35]*	*P = 0.30*	*8.40 [7.55–8.80]*	*8.40 [7.50–9.20]*	*P = 0.50*	*P = 0.35*
Hemoglobin males	*8.20 [7.80–9.15]*	*8.40 [8.03–9.20]*	*P = 0.13*	*8.20 [7.40–8.95]*	*8.90 [8.10–9.25]*	*P = 0.18*	*P = 0.17*
Systemic iron status parameters							
MCV *(fL)*	90.00 [85.30–93.30]	90.01 (SD 5.34)	*P* = 0.08	88.40 [82.50–91.45]	88.65 [84.93–92.95]	*P* = 0.26	*P* = 0.84
Ferritin *(µg/L)*	34.50 [18.50–62.50]	32.00 [17.50–48.50]	***P* < 0.01**	152.50 [111.50–220.25]	117.50 [76.00–163.75]	*P* < 0.01	***P* < 0.001**
Iron *(µmol/L)*	11.10 [7.00–15.60]	13.45 [9.05–19.20]	*P* = 0.10	10.50 [6.73–17.03]	14.10 [11.80–16.25]	*P* = 0.33	*P* = 0.90
Transferrin *(g/L)*	2.50 [2.20–2.90]	2.70 [2.40–3.20]	***P* < 0.001**	2.30 [2.10–2.75]	2.40 [2.20–2.75]	*P* = 0.18	*P* = 0.18
TIBC *(µmol/L)*	63.00 [56.00–73.00]	67.50 [60.00–79.00]	***P* < 0.001**	56.50 [48.50–68.50]	60.50 [54.50–69.50]	*P* = 0.09	*P* = 0.38
TSAT *(%)*	17.50 [11.75–26.25]	18.00 [13.00–29.00]	*P* = 0.29	18.50 [11.75–28.00]	24.50 [19.50–25.25]	*P* = 0.47	*P* = 0.84
Hepcidin *(ng/mL)*	12.39 [6.05–23.35]	5.55 [1.97–12.18]	***P* < 0.001**	57.67 [40.91–70.68]	28.00 [23.25–57.09]	*P* = 0.10	*P* = 0.19
sTfR *(µg/mL)*	7.08 [5.99–9.97]	7.23 [5.98–9.33]	*P* = 0.98	7.64 [5.53–8.66]	7.16 [6.23–7.79]	*P* = 0.40	*P* = 0.50
sTfR/log Ferritin Index	4.98 [3.62–6.36]	5.25 [3.79–6.68]	*P* = 0.32	3.55 [2.43–4.23]	3.41 [2.80–3.98]	*P* = 0.65	*P* = 0.83
Inflammation-associated parameters							
CRP *(mg/L)*	4.60 [1.60–12.00]	1.70 [0.58–7.13]	***P* < 0.01**	10.50 [1.83–37.00]	2.00 [1.38–4.25]	*P* < 0.01	*P* = 0.06
ESR *(mm/hour)*	20.00 [9.00–37.50]	12.50 [4.25–27.00]	***P* < 0.001**	20.50 [8.25–61.00]	9.00 [3.00–21.25]	*P* < 0.05	*P* = 0.60
WBC *(x 10^9/L)*	7.10 [5.73–9.80]	6.55 [4.90–7.83]	***P* < 0.01**	9.45 [7.10–11.35]	7.95 [5.98–10.35]	*P* = 0.06	*P* = 0.42
Neutrophils *(x 10^9/L)*	4.74 [3.84–7.38]	4.00 [3.04–5.18]	***P* < 0.01**	6.85 [4.97–8.85]	4.80 [3.16–6.92]	*P* < 0.01	*P* = 0.22
Platelets *(x 10^9/L)*	327.00 [266.00–385.00]	290.00 [246.50–355.25]	***P* < 0.01**	289.00 [224.00–429.50]	261.00 [216.75–384.00]	*P* = 0.10	*P* = 0.43
cFGF-23 *(pmol/L)*	0.87 [0.48–1.60]	0.82 [0.41–1.75]	*P* = 0.60	0.83 [0.69–1.39]	0.93 [0.41–1.49]	*P* = 0.81	*P* = 0.98
iFGF-23 *(pg/mL)*	10.10 [6.69–12.51]	8.16 [5.51–10.66]	*P* = 0.16	12.25 [5.98–15.65]	7.56 [5.53–13.34]	*P* = 0.31	*P* = 0.60
c/iFGF-23 ratio	0.10 [0.05–0.17]	0.12 [0.05–0.22]	*P* = 0.22	0.08 [0.06–0.13]	0.10 [0.07–0.14]	*P* = 0.51	*P* = 0.65
IL-1β *(pg/mL)*	1.17 [0.93–1.27]	1.11 [0.72–1.29]	*P* = 0.66	1.31 [0.94–1.54]	1.24 [0.88–1.35]	*P* = 0.05	*P* = 0.13
IL-6 *(pg/mL)*	2.29 [1.35–3.31]	1.71 [0.98–2.66]	***P* < 0.05**	2.78 [1.74–6.14]	2.03 [1.50–3.68]	*P* = 0.48	*P* = 0.44
IL-10 *(pg/mL)*	0.95 [0.45–1.55]	1.37 [0.47–1.76]	***P* < 0.01**	1.10 [0.38–1.60]	1.45 [0.59–1.77]	*P* = 0.13	*P* = 1.00
IL-22 *(pg/mL)*	1.15 [0.69–2.26]	0.97 [0.55–1.26]	***P* < 0.01**	1.12 [0.66–1.92]	1.21 [0.63–2.53]	*P* = 0.65	*P* = 0.48
IL-23 *(pg/mL)*	6.84 [5.99–7.82]	7.38 [5.86–9.06]	*P* < 0.05	7.40 [6.57–8.30]	7.31 [6.69–8.49]	*P* = 0.61	*P* = 0.64
TNFα *(pg/mL)*	2.13 [1.72–2.57]	1.73 [0.95–2.17]	***P* < 0.001**	2.15 [1.49–2.67]	1.91 [0.66–2.80]	*P* = 0.13	*P* = 0.88
INF-γ *(pg/mL)*	22.95 [8.39–42.71]	14.30 [6.56–31.25]	*P* < 0.05	22.10 [12.19–51.39]	27.12 [17.81–45.00]	*P* = 0.79	*P* = 0.51
R-SH *(uM)*	238.32 [197.42–274.94]	228.97 [211.41–280.24]	*P* = 0.10	292.44 [249.65–325.68]	290.33 [229.75–307.60]	*P* = 0.28	*P* = 0.08
FCP *(mg/kg)* ‡	497.50 [173.25–1427.50]	147.50 [46.00–1437.50]	*P* = 0.67	1420.00 [276.25–2960.00]	157.50 [108.75–5951.25]	*P* = 1.00	*P* = 0.73
Hypoxia-associated parameters							
EPO *(pg/mL)*	77.44 [46.26–130.19]	65.91 [53.14–122.68]	*P* = 0.20	79.86 [50.59–147.43]	61.82 [33.21–91.52]	*P* < 0.05	*P* = 0.23
MIP-3α *(pg/mL)*	20.04 [12.50–33.37]	16.70 [9.31–26.51]	***P* < 0.05**	19.56 [12.63–26.02]	16.30 [9.49–23.08]	*P* = 0.31	*P* = 0.55
VEGF-A *(pg/mL)*	107.02 [66.57–210.61]	99.39 [55.64–150.61]	***P* < 0.05**	194.38 [87.03–310.10]	210.66 [114.12–320.76]	*P* = 0.86	*P* = 0.51
Other parameters							
MCV *(fL)*	90.00 [85.30–93.30]	90.01 (± 5.34)	*P* = 0.08	88.40 [82.50–91.45]	88.65 [84.93–92.95]	*P* = 0.26	*P* = 0.84
LDH *(U/L)*	156.50 [132.75–203.50]	157.00 [128.00–191.00]	*P* = 0.58	175.50 [150.75–235.25]	187.50 [147.25–209.00]	*P* = 0.71	*P* = 0.75
Albumin *(g/L)*	41.00 [39.00–44.00]	42.00 [41.00–44.00]	*P* = 0.05	41.50 [39.75–45.25]	42.50 [41.00–44.25]	*P* = 0.53	*P* = 0.70

*Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. ID: iron deficiency, NON-ID: iron-sufficient status MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 10. Change in biochemical parameters in patients with ulcerative colitis, stratified by iron-deficient or iron-sufficient status at baseline.

	ID baseline (n = 43)	ID week 6 (n = 41)	Paired analysis	NON-ID baseline (n = 13)	NON-ID week 6 (n = 13)	Paired analysis	Δ difference between groups
Hemoglobin *(mmol/L)*	**8.10 (SD 0.95)**	**8.00 [7.60–8.70]**	*P* = 0.71	**8.40 [7.80–8.65]**	**8.50 [7.90–8.65]**	P = 0.35	P = 0.66
Hemoglobin females	*7.70 [7.30–8.00]*	*7.80 [7.00–8.00]*	*P = 0.53*	*NA*	*NA*	*NA*	*NA*
Hemoglobin males	*8.40 [7.83–9.18]*	*8.15 [7.75–9.05]*	*P = 0.35*	*8.40 [7.80–8.90]*	*8.60 [8.30–8.90]*	*P = 0.06*	*P = 0.54*
Systemic iron status parameters							
Ferritin *(µg/L)*	31.00 [22.00–56.00]	29.00 [18.75–43.00]	*P* = 0.15	139.00 [115.00–208.50]	98.00 [71.50–191.50]	*P* < 0.05	***P* < 0.01**
Iron *(µmol/L)*	13.00 [9.40–18.00]	13.25 [8.93–17.75]	*P* = 0.43	16.00 [10.75–20.05]	15.80 [11.80–19.45]	*P* = 0.41	*P* = 0.27
Transferrin *(g/L)*	2.50 [2.20–2.70]	2.60 [2.30–2.88]	*P* < 0.05	2.25 [2.13–2.40]	2.35 [2.05–2.50]	*P* = 0.18	*P* = 0.57
TIBC *(µmol/L)*	62.00 [56.00–67.00]	65.00 [58.00–72.50]	*P* < 0.05	57.00 [50.00–59.50]	57.00 [47.00–63.00]	*P* = 0.39	*P* = 0.24
TSAT *(%)*	19.50 [14.75–27.75]	20.50 [13.00–27.75]	*P* = 0.15	30.00 [20.00–35.50]	28.00 [22.50–36.00]	*P* = 0.39	*P* = 0.18
Hepcidin *(ng/mL)*	5.03 [2.62–14.23]	7.54 [1.75–15.07]	*P* = 0.96	29.92 [17.87–64.93]	16.56 [11.57–47.44]	*P* = 0.09	*P* < 0.05
sTfR *(µg/mL)*	7.73 [5.65–10.91]	8.86 [6.22–10.88]	*P* = 0.57	6.20 [5.33–8.98]	7.56 [6.31–9.60]	*P* = 0.09	*P* = 0.21
sTfR/log Ferritin Index	5.14 [3.66–7.18]	5.64 [3.88–8.68]	*P* = 0.28	2.80 [2.37–4.30]	3.53 [3.14–4.59]	*P* < 0.01	*P* = 0.44
Inflammation-associated parameters							
CRP *(mg/L)*	3.00 [1.30–5.00]	2.25 [1.13–4.98]	*P* = 0.30	1.70 [0.80–15.80]	1.20 [0.50–5.50]	*P* = 0.17	*P* = 0.54
ESR *(mm/hour)*	16.00 [6.00–37.00]	14.00 [6.00–30.00]	*P* = 0.14	17.00 [5.50–40.50]	12.00 [8.00–34.00]	*P* = 0.31	*P* = 0.99
WBC *(x 10^9/L)*	7.40 [5.70–8.80]	6.35 [5.20–7.30]	***P* < 0.01**	7.90 [5.95–10.25]	6.30 [4.95–7.45]	*P* < 0.01	*P* = 0.28
Neutrophils *(x 10^9/L)*	5.04 [3.66–7.64]	4.31 [2.81–4.83]	***P* < 0.01**	6.00 [4.27–7.85]	3.95 [2.97–5.18]	*P* < 0.01	*P* = 0.38
Platelets *(x 10^9/L)*	296.00 [241.00–345.00]	265.00 [242.00–313.00]	*P* = 0.23	262.00 [237.00–358.00]	270.00 [221.00–357.50]	*P* = 0.92	*P* = 0.71
cFGF-23 *(pmol/L)*	0.98 [0.46–1.39]	1.05 [0.58–1.58]	*P* = 0.55	0.54 [0.31–1.46]	1.30 [0.52–2.00]	*P* = 0.14	*P* = 0.20
iFGF-23 *(pg/mL)*	10.96 [7.92–14.64]	10.37 [7.50–13.78]	*P* = 0.50	8.46 [5.60–16.65]	9.67 [6.54–12.08]	*P* = 0.25	*P* = 0.49
c/iFGF-23 ratio	0.09 [0.04–0.17]	0.08 [0.05–0.18]	*P* = 0.35	0.05 [0.04–0.32]	0.11 [0.05–0.20]	*P* = 0.86	*P* = 0.50
IL-1β *(pg/mL)*	0.83 [0.15–1.28]	1.03 [0.58–1.36]	*P* = 0.47	0.32 [0.05–1.00]	0.43 [0.00–1.12]	*P* = 0.59	*P* = 0.60
IL-6 *(pg/mL)*	1.79 [0.77–5.00]	1.57 [1.10–3.70]	*P* = 0.51	1.33 [0.80–4.48]	1.06 [0.72–2.09]	*P* = 0.09	*P* = 0.28
IL-10 *(pg/mL)*	0.96 [0.59–1.58]	0.89 [0.60–1.65]	*P* = 0.42	0.97 [0.55–1.43]	0.77 [0.40–2.26]	*P* = 0.75	*P* = 0.75
IL-22 *(pg/mL)*	1.23 [0.72–1.72]	0.84 [0.53–1.38]	*P* < 0.01	1.40 [0.99–2.58]	1.18 [0.80–2.05]	*P* = 0.55	*P* = 0.40
IL-23 *(pg/mL)*	5.68 [0.56–8.76]	5.19 [0.62–7.50]	*P* = 0.23	0.83 [0.57–7.87]	4.10 [0.18–8.63]	*P* = 0.14	*P* = 0.47
TNFα *(pg/mL)*	2.05 [1.51–3.10]	2.01 [1.31–3.21]	*P* = 0.87	1.95 [1.15–3.78]	1.68 [0.80–2.96]	*P* = 0.10	*P* = 0.24
INF-γ *(pg/mL)*	15.20 [7.63–24.70]	12.14 [7.41–26.85]	*P* = 0.78	15.00 [11.00–25.08]	15.96 [12.44–39.11]	*P* = 0.33	*P* = 0.32
MIP3α *(pg/mL)*	20.90 [11.73–31.57]	21.10 [12.76–29.56]	*P* = 0.58	14.76 [10.31–28.66]	13.71 [10.80–17.36]	*P* = 0.45	*P* = 0.79
VEGF-A *(pg/mL)*	120.09 [79.12–177.55]	104.44 [68.59–184.14]	*P* = 0.08	119.14 [71.24–258.15]	152.57 [70.84–197.32]	*P* = 0.15	*P* < 0.05
R-SH *(uM)*	216.68 [189.53–266.80]	235.52 (SD 61.26)	*P* = 0.37	212.39 [182.349–240.87]	223.70 [183.85–262.80]	*P* = 0.55	*P* = 0.86
FCP *(mg/kg) ‡*	842.50 [255.00–1925.25]	138.00 [40.50–640.00]	***P* < 0.001**	830.00 [400.00–1650.00]	235.00 [73.25–802.50]	*P* = 0.66	*P* = 0.55
Hypoxia-associated parameters							
EPO *(pg/mL)*	89.78 [60.69–137.68]	100.82 [65.85–160.79]	*P* = 0.93	76.89 [57.32–83.92]	63.84 [51.52–100.81]	*P* = 0.86	*P* = 0.81
MIP-3α *(pg/mL)*	20.90 [11.73–31.57]	21.10 [12.76–29.56]	*P* = 0.58	14.76 [10.31–28.66]	13.71 [10.80–17.36]	*P* = 0.45	*P* = 0.79
VEGF-A *(pg/mL)*	120.09 [79.12–177.55]	104.44 [68.59–184.14]	*P* = 0.08	119.14 [71.24–258.15]	152.57 [70.84–197.32]	*P* = 0.15	*P* < 0.05
Other parameters							
MCV *(fL)*	91.00 [87.10–94.00]	90.50 [85.60–94.60]	*P* = 0.51	93.30 [88.70–95.80]	92.20 [89.15–97.20]	*P* = 0.81	*P* = 0.97
LDH *(U/L)*	175.50 [149.75–219.50]	199.00 [158.00–276.00]	*P* = 0.13	185.00 [160.50–209.75]	186.00 [171.50–251.00]	*P* = 0.94	*P* = 0.54
Albumin *(g/L)*	42.00 [40.00–43.00]	42.00 [40.00–44.00]	*P* = 0.23	40.00 [37.00–43.00]	40.00 [39.00–42.00]	*P* = 0.22	*P* = 0.93

*Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. ID: iron deficiency, NON-ID: iron-sufficient status MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 11. Changes in biochemical parameters in patients with IBD over the course of induction therapy with either infliximab or vedolizumab, stratified by Biological-naive or Biological-experienced status.

	Biological naive baseline (n = 67)	Biological naive week 6 (n = 66)	Paired analysis	Biological experienced baseline (n = 55)	Biological experienced week 6 (n = 53)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**8.10 [7.40–8.53]**	**8.10 [7.70–8.70]**	***P* < 0.05**	**8.00 [7.60–8.50]**	**8.00 [7.50–8.90]**	*P* = 0.34	*P* = 0.54
Hemoglobin females	*7.75 [7.23–8.30]*	*7.75 [7.23–8.28]*	*P = 0.45*	*7.70 [7.30–8.43]*	*7.70 [7.40–8.15]*	*P = 0.96*	*P = 0.74*
Hemoglobin males	*8.35 (SD 0.93)*	*8.40 [8.00–8.95]*	***P* < 0.05**	*8.30 [7.90–9.05]*	*8.55 [7.85–9.23]*	*P = 0.15*	*P = 0.83*
Systemic iron status parameters							
Ferritin *(µg/L)*	46.00 [24.00–92.00]	40.00 [24.50–74.50]	***P* < 0.001**	43.00 [22.00–92.00]	36.00 [22.25–68.50]	***P* < 0.01**	*P* = 0.90
Iron *(µmol/L)*	14.00 [9.00–19.00]	14.80 [11.30–19.00]	*P* = 0.47	10.70 [8.00–15.60]	12.95 [8.05–16.03]	*P* = 0.36	*P* = 0.91
Transferrin *(g/L)*	2.40 [2.20–2.80]	2.50 [2.30–3.00]	***P* < 0.001**	2.40 [2.20–2.73]	2.60 (SD 0.45)	***P* < 0.01**	*P* = 0.84
TIBC *(µmol/L)*	61.00 [56.00–69.00]	63.00 [57.00–74.00]	***P* < 0.001**	60.50 [55.00–69.50]	65.65 (SD 11.57)	***P* < 0.01**	*P* = 0.98
TSAT *(%)*	24.00 [14.00–31.00]	24.00 [15.00–29.00]	*P* = 0.97	18.00 [12.00–24.75]	19.50 [12.25–26.00]	P = 0.60	*P* = 0.69
Hepcidin *(ng/mL)*	12.43 [5.95–29.21]	8.35 [2.53–21.20]	***P* < 0.001**	13.93 [4.41–28.46]	11.65 [4.02–21.98]	*P* = 0.06	*P* = 0.44
sTfR *(µg/mL)*	7.39 [5.95–10.22]	7.20 [5.94–9.36]	*P* = 0.21	7.34 [5.60–9.64]	7.71 [6.68–9.84]	***P* < 0.01**	*P* < 0.01
sTfR/log Ferritin Index	4.48 [3.43–6.08]	4.44 [3.45–6.36]	*P* = 0.53	4.73 [3.39–6.52]	5.25 [3.62–7.04]	***P* < 0.01**	*P* < 0.05
Inflammation-associated parameters							
CRP *(mg/L)*	4.50 [1.60–12.00]	1.70 [0.65–4.95]	***P* < 0.001**	3.00 [1.45–11.00]	2.40 [1.23–8.70]	*P* < 0.05	*P* = 0.18
ESR *(mm/hour)*	16.00 [7.00–37.50]	11.00 [5.00–24.00]	***P* < 0.001**	18.00 [9.00–40.00]	14.00 [6.75–32.25]	*P* = 0.07	*P* = 0.07
WBC *(x 10^9/L)*	7.20 [5.70–9.20]	6.30 [4.55–7.30]	***P* < 0.001**	8.20 [6.20–11.20]	6.60 [5.75–8.90]	***P* < 0.001**	*P* = 0.63
Neutrophils *(x 10^9/L)*	5.01 [3.59–6.94]	3.83 [2.66–4.79]	***P* < 0.001**	5.82 [4.02–9.04]	4.20 [3.20–6.22]	***P* < 0.001**	*P* = 0.35
Platelets *(x 10^9/L)*	294.50 [246.75–373.75]	271.00 [236.00–349.50]	***P* < 0.01**	310.50 [248.75–365.50]	288.00 [245.00–337.00]	*P* = 0.19	*P* = 0.22
cFGF-23 *(pmol/L)*	1.03 [0.58–1.61]	0.96 [0.52–1.73]	*P* = 0.34	0.76 [0.43–1.34]	1.01 [0.46–1.64]	*P* = 0.49	*P* = 0.91
iFGF-23 *(pg/mL)*	10.13 [5.93–13.55]	8.65 [5.69–13.04]	*P* = 0.44	10.25 [8.02–14.13]	9.23 [7.53–12.40]	*P* = 0.23	*P* = 0.73
c/iFGF-23 ratio	0.10 [0.05–0.20]	0.10 [0.05–0.21]	*P* = 0.69	0.07 [0.04–0.12]	0.10 [0.04–0.17]	*P* = 0.62	*P* = 0.90
IL-1β *(pg/mL)*	1.23 [0.46–1.32]	1.08 [0.66–1.29]	*P* = 0.16	0.97 [0.21–1.23]	1.03 [0.85–1.36]	*P* = 0.65	*P* = 0.18
IL-6 *(pg/mL)*	2.05 [0.95–3.65]	1.39 [0.92–2.70]	***P* < 0.05**	2.46 [1.08–4.75]	2.04 [1.33–2.95]	*P* = 0.22	*P* = 0.42
IL-10 *(pg/mL)*	1.14 [0.57–1.56]	1.20 [0.45–1.78]	*P* = 0.07	0.81 [0.50–1.56]	0.78 [0.51–1.59]	*P* = 0.26	*P* = 0.66
IL-22 *(pg/mL)*	1.15 [0.69–1.62]	0.94 [0.62–1.27]	***P* < 0.01**	1.24 [0.78–2.68]	0.97 [0.57–1.67]	***P* < 0.01**	*P* = 0.26
IL-23 *(pg/mL)*	7.23 [6.42–7.92]	6.92 [1.71–8.22]	*P* = 0.71	6.00 [0.65–7.87]	7.04 [0.79–8.76]	*P* = 0.49	*P* = 0.98
TNFα *(pg/mL)*	2.08 [1.44–2.65]	1.62 [0.75–2.12]	***P* < 0.001**	2.07 [1.68–2.84]	2.10 [1.69–3.25]	*P* = 0.72	***P* < 0.01**
INF-γ *(pg/mL)*	18.40 [7.83–31.37]	15.32 [6.59–28.01]	*P* = 0.72	16.71 [8.77–30.27]	14.65 [7.61–33.49]	*P* = 0.12	*P* = 0.36
R-SH *(uM)*	233.56 [190.86–271.41]	241.22 [205.73–302.02]	***P* < 0.05**	235.14 [206.07–277.99]	225.84 [194.99–267.37]	*P* = 0.21	*P* < 0.01
FCP *(mg/kg)* ‡	745.00 [248.75–1665.00]	61.50 [40.00–180.75]	***P* < 0.01**	805.00 [258.50–2158.50]	180.00 [105.00–1760.00]	*P* = 0.07	*P* = 0.43
Hypoxia-associated parameters							
EPO *(pg/mL)*	88.20 [64.74–136.51]	70.00 [55.86–126.77]	***P* < 0.01**	74.33 [40.19–105.81]	68.32 [52.45–112.58]	*P* = 0.65	*P* = 0.05
MIP-3α *(pg/mL)*	19.94 [11.73–31.83]	18.19 [11.28–25.64]	***P* < 0.01**	19.51 [10.70–28.61]	15.34 [10.16–27.16]	*P* = 0.75	*P* = 0.06
VEGF-A *(pg/mL)*	124.06 [77.26–220.09]	109.18 [64.70–182.00]	*P* < 0.05	115.60 [77.56–211.16]	118.48 [67.60–201.72]	*P* = 0.38	*P* = 0.35
Other parameters							
MCV *(fL)*	90.55 [85.88–93.55]	90.80 [86.20–93.95]	*P* = 0.58	90.25 [85.55–93.30]	89.70 [86.30–94.10]	*P* = 0.40	*P* = 0.58
LDH *(U/L)*	167.00 [140.00–205.00]	173.00 [152.00–230.00]	*P* < 0.05	172.00 [149.00–222.00]	179.00 [137.00–212.00]	*P* = 0.87	*P* = 0.16
Albumin *(g/L)*	42.00 [40.00–44.00]	42.00 [41.00–44.00]	***P* < 0.01**	41.00 [39.50–43.00]	42.00 [40.00–44.00]	*P* = 0.41	*P* = 0.28

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in ***bold*** *represent statistical significance after adjustment for multiple testing.*

Supplementary table 12. Changes in biochemical parameters in patients with Crohn's disease over the course of induction therapy with either infliximab or vedolizumab, stratified by Biological-naive or Biological-experienced status.

	Biological naive baseline (n = 39)	Biological naive week 6 (n = 38)	Paired analysis	Biological experienced baseline (n = 27)	Biological experienced week 6 (n = 27)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**8.10 [7.38–8.43]**	**8.20 [7.38–8.70]**	***P* < 0.05**	**7.90 [7.30–8.50]**	**8.00 [7.40–8.98]**	*P* = 0.45	*P* = 0.44
Hemoglobin females	*7.80 [7.15–8.40]*	*7.80 [7.25–8.55]*	*P = 0.06*	*7.70 [7.30–8.50]*	*7.65 [7.40–8.53]*	*P = 1.00*	*P = 0.32*
Hemoglobin males	*8.20 [7.65–9.25]*	*8.40 [8.10–9.10]*	*P = 0.11*	*8.15 [7.90–8.80]*	*8.85 [7.78–9.28]*	*P = 0.21*	*P = 0.71*
Systemic iron status parameters							
Ferritin *(µg/L)*	39.00 [23.00–89.00]	32.00 [23.25–68.50]	***P* < 0.01**	58.00 [29.00–102.00]	50.00 [27.00–70.25]	*P* < 0.05	*P* = 0.51
Iron *(µmol/L)*	12.00 [8.00–16.50]	14.05 [10.75–19.20]	*P* = 0.11	9.50 [6.30–15.60]	13.35 [7.75–15.88]	*P* = 0.40	*P* = 0.89
Transferrin *(g/L)*	2.55 [2.20–2.90]	2.70 [2.30–3.20]	***P* < 0.001**	2.40 [2.20–2.90]	2.55 [2.38–2.93]	*P* = 0.06	*P* = 0.22
TIBC *(µmol/L)*	63.00 [55.00–74.00]	68.50 [57.00–79.50]	***P* < 0.001**	61.00 [55.00–73.00]	64.50 [59.25–74.00]	*P* = 0.06	*P* = 0.25
TSAT *(%)*	20.00 [11.75–27.00]	20.41 [15.00–29.00]	*P* = 0.39	16.50 [11.25–24.75]	19.50 [10.75–25.25]	*P* = 0.38	*P* = 0.81
Hepcidin *(ng/mL)*	12.43 [6.96–39.65]	6.37 [2.04–18.92]	***P* < 0.001**	21.95 [10.18–55.91]	14.39 [4.97–26.86]	*P* = 0.06	*P* = 0.62
sTfR *(µg/mL)*	7.60 [5.95–10.20]	7.33 [5.75–9.23]	*P* = 0.47	7.07 [6.00–8.94]	7.11 [6.20–8.35]	*P* = 0.69	*P* = 0.46
sTfR/log Ferritin Index	4.68 [3.48–6.08]	4.66 [3.39–6.46]	*P* = 0.61	4.59 [3.40–5.47]	4.57 [3.25–6.13]	*P* = 0.23	*P* = 0.38
Inflammation-associated parameters							
CRP *(mg/L)*	5.20 [1.60–13.00]	2.00 [0.73–4.70]	***P* < 0.001**	6.25 [1.83–15.25]	1.70 [1.28–11.50]	*P* < 0.01	*P* = 0.96
ESR *(mm/hour)*	20.00 [8.00–35.50]	11.00 [3.50–21.00]	***P* < 0.001**	21.00 [10.50–46.50]	14.00 [5.50–33.50]	*P* < 0.05	*P* = 0.39
WBC *(x 10^9/L)*	7.00 [5.70–9.70]	6.40 [4.48–7.83]	***P* < 0.01**	8.20 [7.00–11.60]	7.50 [6.15–10.35]	*P* < 0.05	*P* = 0.98
Neutrophils *(x 10^9/L)*	4.68 [3.80–7.11]	3.70 [2.81–4.88]	***P* < 0.01**	5.65 [4.04–9.17]	4.65 [3.38–6.82]	*P* < 0.05	*P* = 0.79
Platelets *(x 10^9/L)*	329.00 [258.50–385.00]	284.00 [242.25–361.75]	***P* < 0.01**	324.50 [248.25–396.75]	287.00 [241.00–340.50]	*P* < 0.05	*P* = 0.46
cFGF-23 *(pmol/L)*	1.07 [0.71–1.63]	0.89 [0.44–1.84]	*P* = 0.48	0.72 [0.41–1.37]	0.75 [0.32–1.60]	*P* = 0.71	*P* = 0.37
iFGF-23 *(pg/mL)*	10.42 [5.93–13.14]	8.11 [5.45–11.31]	*P* = 0.36	9.81 [8.02–13.94]	8.08 [5.60–10.24]	*P* = 0.09	*P* = 0.52
c/iFGF-23 ratio	0.11 [0.06–0.19]	0.12 [0.06–0.22]	*P* = 0.19	0.08 [0.03–0.12]	0.08 [0.04–0.18]	*P* = 0.57	*P* = 0.64
IL-1β *(pg/mL)*	1.23 [1.09–1.32]	1.13 [0.89–1.29]	*P* = 0.10	1.10 [0.47–1.58]	1.03 [0.58–1.40]	*P* = 0.80	*P* = 0.42
IL-6 *(pg/mL)*	2.38 [1.53–3.21]	1.71 [0.99–2.69]	***P* < 0.05**	2.66 [0.81–3.59]	2.02 [1.19–2.87]	*P* = 0.72	*P* = 0.17
IL-10 *(pg/mL)*	1.36 [0.57–1.56]	1.47 [0.54–1.79]	***P* < 0.01**	0.52 [0.38–1.42]	0.68 [0.47–1.58]	*P* < 0.01	*P* = 0.98
IL-22 *(pg/mL)*	1.10 [0.64–1.72]	1.03 [0.56–1.26]	*P* < 0.05	1.15 [0.72–3.08]	1.01 [0.45–2.13]	*P* = 0.07	*P* = 0.45
IL-23 *(pg/mL)*	7.23 [6.74–7.91]	7.25 [6.48–8.82]	*P* = 0.22	6.26 [0.75–7.82]	7.66 [0.93–9.26]	*P* < 0.05	*P* = 0.47
TNFα *(pg/mL)*	2.20 [1.63–2.53]	1.62 [0.91–2.25]	***P* < 0.001**	2.03 [1.52–2.58]	2.02 [1.15–2.65]	*P* = 0.24	*P* = 0.13
INF-γ *(pg/mL)*	25.91 [10.20–42.78]	16.34 [6.56–27.34]	*P* = 0.16	17.50 [8.10–55.88]	18.57 [7.68–46.95]	*P* = 0.18	*P* = 0.86
R-SH *(uM)*	244.32 [191.64–278.81]	241.22 [211.79–301.38]	*P* = 0.10	260.15 [212.25–291.56]	242.32 [206.69–295.59]	*P* = 0.46	*P* = 0.14
FCP *(mg/kg)* ‡	682.50 [228.75–1802.50]	66.50 [40.00–138.75]	*P* = 0.11	524.50 [288.25–2875.00]	647.50 [116.25–2240.00]	*P* = 0.95	*P* = 0.41
Hypoxia-associated parameters							
EPO *(pg/mL)*	100.77 [63.17–148.64]	66.91 [53.95–122.78]	***P* < 0.05**	60.05 [39.62–89.33]	59.96 [42.72–84.00]	*P* = 0.78	*P* = 0.11
MIP-3α *(pg/mL)*	19.80 [12.68–30.02]	17.37 [9.66–23.97]	***P* < 0.01**	22.88 [11.32–34.31]	15.65 [8.45–47.49]	*P* = 0.37	*P* = 0.20
VEGF-A *(pg/mL)*	125.30 [85.92–225.89]	110.87 [67.97–172.88]	*P* = 0.10	107.35 [76.84–235.19]	117.92 [54.61–199.55]	*P* = 0.15	*P* = 0.68
Other parameters							
MCV *(fL)*	89.30 (SD 5.02)	90.65 [85.65–93.48]	*P* < 0.05	90.20 [84.53–92.90]	89.35 [86.03–92.48]	*P* = 0.39	*P* = 0.76
LDH *(U/L)*	156.00 [134.00–203.00]	164.00 [142.00–203.00]	*P* = 0.08	168.00 [137.50–225.50]	157.00 [126.50–191.00]	*P* = 0.34	*P* = 0.06
Albumin *(g/L)*	42.00 [40.00–44.00]	43.00 [41.00–44.50]	*P* < 0.05	41.00 [39.00–43.25]	42.00 [40.00–44.00]	*P* = 0.57	*P* = 0.30

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in ***bold*** *represent statistical significance after adjustment for multiple testing.*

Supplementary table 13. Changes in biochemical parameters in patients with ulcerative colitis over the course of induction therapy with either infliximab or vedolizumab, stratified by Biological-naive or Biological-experienced status.

	Biological naive baseline (n = 28)	Biological naive week 6 (n = 27)	Paired analysis	Biological experienced baseline (n = 28)	Biological experienced week 6 (n = 27)	Paired analysis	Δ difference between groups
Hemoglobin *(mmol/L)*	**8.18 (SD 0.91)**	**8.00 [7.70–8.70]**	*P* = 0.58	**8.10 [7.63–8.73]**	**8.00 [7.65–8.65]**	*P* = 0.57	*P* = 0.92
Hemoglobin females	*7.70 [7.30–8.10]*	*7.70 [6.90–8.00]*	*P = 0.09*	*7.70 [7.50–8.40]*	*7.80 [7.50–8.10]*	*P = 0.89*	*P = 0.20*
Hemoglobin males	*8.30 [7.80–8.95]*	*8.50 [7.90–8.70]*	*P = 0.11*	*8.50 [7.95–9.20]*	*8.50 [7.83–9.18]*	*P = 0.41*	*P = 0.69*
Systemic iron status parameters							
Ferritin *(µg/L)*	54.50 [30.00–101.00]	43.00 [26.00–82.00]	*P* < 0.05	31.00 [21.25–89.00]	31.50 [22.00–67.75]	*P* = 0.14	*P* = 0.59
Iron *(µmol/L)*	15.90 [11.48–20.23]	14.80 [11.60–19.00]	*P* = 0.49	11.10 [8.48–16.60]	12.25 [7.95–17.95]	*P* = 0.77	*P* = 0.53
Transferrin *(g/L)*	2.40 [2.28–2.60]	2.40 [2.28–2.73]	*P* = 0.18	2.35 [2.20–2.68]	2.60 [2.30–2.85]	*P* < 0.05	*P* = 0.24
TIBC *(µmol/L)*	60.50 [56.25–65.00]	60.00 [55.00–69.00]	*P* = 0.30	59.50 [54.25–67.00]	65.00 [57.75–73.25]	*P* < 0.05	*P* = 0.18
TSAT *(%)*	27.00 [17.00–34.00]	27.00 [17.00–30.00]	*P* = 0.33	18.00 [14.25–26.00]	18.50 [12.75–27.25]	*P* = 0.86	*P* = 0.56
Hepcidin *(ng/mL)*	12.43 [5.02–23.89]	11.53 [3.39–37.27]	*P* = 0.33	4.93 [2.96–17.73]	9.94 [2.51–15.85]	*P* = 0.41	*P* = 0.87
sTfR *(µg/mL)*	7.29 [5.90–10.70]	6.88 [5.98–9.69]	*P* = 0.25	8.44 [5.29–10.40]	9.53 [7.06–13.46]	***P* < 0.01**	*P* < 0.05
sTfR/log Ferritin Index	4.27 [3.40–6.05]	3.96 [3.46–6.22]	*P* = 0.75	4.78 [3.34–6.79]	5.81 [3.80–10.41]	***P* < 0.01**	*P* < 0.05
Inflammation-associated parameters							
CRP *(mg/L)*	3.40 [1.25–5.75]	1.70 [0.60–5.00]	*P* < 0.05	2.45 [0.98–4.98]	2.85 [1.18–5.25]	*P* = 0.81	*P* = 0.07
ESR *(mm/hour)*	13.50 [6.00–41.75]	12.00 [6.00–31.50]	*P* < 0.01	16.50 [6.25–27.50]	15.00 [9.50–30.50]	*P* = 0.98	*P* = 0.12
WBC *(x 10^9/L)*	7.35 [5.48–8.50]	5.80 [4.60–7.10]	*P* < 0.01	8.15 [5.83–10.75]	6.55 [5.50–8.38]	***P* < 0.01**	*P* = 0.41
Neutrophils *(x 10^9/L)*	5.04 [3.38–6.02]	4.14 [2.30–4.82]	*P* < 0.05	6.47 [3.89–9.03]	4.12 [2.97–5.13]	***P* < 0.001**	*P* = 0.10
Platelets *(x 10^9/L)*	263.50 [235.25–319.75]	258.00 [218.00–299.00]	*P* = 0.08	308.00 [248.25–355.75]	289.00 [243.50–341.50]	*P* = 0.91	*P* = 0.25
cFGF-23 *(pmol/L)*	0.89 [0.37–1.45]	1.04 [0.60–1.42]	*P* = 0.66	0.86 [0.45–1.33]	1.29 [0.52–1.64]	*P* = 0.24	*P* = 0.46
iFGF-23 *(pg/mL)*	9.14 [5.77–18.08]	9.71 [5.81–14.24]	*P* = 0.96	11.85 [8.02–14.58]	9.86 [8.42–13.08]	*P* = 0.86	*P* = 0.87
c/iFGF-23 ratio	0.07 [0.03–0.21]	0.08 [0.05–0.22]	*P* = 0.35	0.06 [0.04–0.12]	0.10 [0.05–0.017]	*P* = 0.91	*P* = 0.40
IL-1β *(pg/mL)*	0.46 [0.04–1.36]	0.94 [0.09–1.27]	*P* = 0.89	0.86 [0.15–1.15]	1.01 [0.75–1.36]	*P* = 0.43	*P* = 0.68
IL-6 *(pg/mL)*	1.22 [0.74–4.48]	1.09 [0.65–3.60]	*P* = 0.34	2.38 [1.09–5.00]	2.14 [1.33–3.53]	*P* = 0.24	*P* = 1.00
IL-10 *(pg/mL)*	0.89 [0.49–1.52]	0.77 [0.44–1.51]	*P* = 0.68	1.34 [0.69–1.57]	0.92 [0.59–1.68]	*P* = 0.43	*P* = 0.64
IL-22 *(pg/mL)*	1.22 [0.70–1.56]	0.87 [0.66–1.40]	*P* = 0.11	1.32 [0.93–2.46]	0.90 [0.62–1.60]	*P* < 0.05	*P* = 0.34
IL-23 *(pg/mL)*	6.17 [0.78–12.37]	1.71 [0.19–7.32]	*P* = 0.16	1.23 [0.46–8.13]	6.56 [0.57–8.62]	*P* = 0.31	*P* = 0.61
TNFα *(pg/mL)*	1.75 [1.17–3.11]	1.48 [0.60–2.03]	*P* < 0.05	2.07 [1.86–3.14]	2.90 [1.95–3.52]	*P* = 0.15	*P* < 0.01
INF-γ *(pg/mL)*	12.20 [5.96–19.48]	12.91 [6.38–32.97]	*P* = 0.10	15.82 [11.00–25.86]	13.79 [7.54–27.07]	*P* = 0.36	*P* = 0.09
MIP3α *(pg/mL)*	20.68 [10.66–32.00]	20.17 [12.74–35.24]	*P* = 0.15	17.87 [10.58–27.79]	15.34 [10.21–26.16]	*P* = 0.78	*P* = 0.20
VEGF-A *(pg/mL)*	122.08 [73.51–192.35]	99.21 [54.54–189.68]	*P* = 0.18	117.37 [81.51–165.53]	118.92 [77.88–201.72]	*P* = 0.80	*P* = 0.31
R-SH *(uM)*	219.15 [188.11–265.65]	244.48 [192.77–309.27]	*P* = 0.06	221.04 (SD 47.69)	215.44 (SD 48.84)	*P* = 0.43	*P* < 0.05
FCP *(mg/kg)* ‡	815.00 [242.00–1742.50]	61.50 [40.75–373.75]	*P* < 0.05	830.00 [255.00–1833.50]	170.00 [41.00–970.00]	*P* < 0.05	*P* = 1.00
Hypoxia-associated parameters							
EPO *(pg/mL)*	83.63 [69.42–128.34]	88.93 [57.59–136.11]	*P* = 0.22	80.44 [51.83–135.05]	92.23 [65.03–156.26]	*P* = 0.44	*P* = 0.21
MIP-3α *(pg/mL)*	20.68 [10.66–32.00]	20.17 [12.74–35.24]	*P* = 0.15	17.87 [10.58–27.79]	15.34 [10.21–26.16]	*P* = 0.78	*P* = 0.20
VEGF-A *(pg/mL)*	122.08 [73.51–192.35]	99.21 [54.54–189.68]	*P* = 0.18	117.37 [81.51–165.53]	118.92 [77.88–201.72]	*P* = 0.80	*P* = 0.31
Other parameters							
MCV *(fL)*	91.85 [87.15–94.90]	90.80 [86.70–95.10]	*P* = 0.14	90.55 [87.13–94.58]	91.00 [87.65–94.65]	*P* = 0.73	*P* = 0.22
LDH *(U/L)*	186.00 [145.75–215.75]	188.50 [164.50–255.75]	*P* = 0.17	174.00 [153.00–211.50]	200.50 [163.75–266.25]	*P* = 0.48	*P* = 0.76
Albumin *(g/L)*	42.00 [39.25–44.50]	42.00 [40.00–44.25]	*P* = 0.08	41.00 [40.00–43.00]	41.50 [40.00–43.25]	*P* = 0.50	*P* = 0.63

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO:

*erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 14. Changes in biochemical parameters in patients with ulcerative colitis over the course of induction therapy with either infliximab or vedolizumab, stratified by the extent of colon involvement.

	Montreal E3 baseline (n = 30)	Montreal E3 week 6 (n = 28)	Paired analysis	Montreal E1 and E2 baseline (n = 25)	Montreal E1 and E2 week 6 (n = 25)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**8.30 [7.78–9.13]**	**8.00 [7.70–8.70]**	*P* = 0.71	**7.90 [7.55–8.55]**	**8.00 [7.65–08.60]**	*P* = 0.17	*P* = 0.27
Hemoglobin females	*7.85 [7.53–8.33]*	*7.75 [7.53–8.05]*	*P = 0.62*	*7.55 [7.28–8.00]*	*7.70 [6.75–8.00]*	*P = 0.39*	*P = 0.65*
Hemoglobin males	*8.60 [8.03–9.28]*	*8.60 [7.90–9.40]*	*P = 1.00*	*8.20 [7.80–8.65]*	*8.50 [7.93–8.70]*	*P < 0.05*	*P = 0.15*
Systemic iron status parameters							
Ferritin *(µg/L)*	43.50 [24.00–85.50]	37.00 [22.00–73.00]	*P* = 0.45	46.00 [25.00–106.00]	42.00 [24.50–84.50]	***P* < 0.01**	*P* < 0.05
Iron *(µmol/L)*	13.40 [9.33–20.15]	15.10 [10.10–19.00]	*P* = 1.00	13.90 [9.70–18.50]	12.90 [9.15–18.15]	*P* = 0.62	*P* = 0.78
Transferrin *(g/L)*	2.50 [2.20–2.65]	2.50 [2.30–2.93]	*P* = 0.13	2.30 [2.20–2.50]	2.50 [2.20–2.75]	*P* < 0.05	*P* = 0.47
TIBC *(µmol/L)*	61.50 [57.00–67.00]	63.00 [58.00–73.00]	*P* = 0.30	58.00 [54.50–63.00]	62.00 [55.00–69.00]	*P* < 0.05	*P* = 0.34
TSAT *(%)*	21.50 [15.00–34.00]	26.00 [13.00–29.00]	*P* = 0.80	27.00 [16.25–31.75]	21.00 [13.50–28.50]	*P* = 0.31	*P* = 0.78
Hepcidin *(ng/mL)*	8.75 [3.63–22.66]	11.57 [2.92–18.75]	*P* = 0.50	10.89 [3.37–21.90]	10.30 [5.76–23.34]	*P* = 0.24	*P* = 0.59
sTfR *(µg/mL)*	6.94 [5.32–9.45]	7.09 [6.22–8.83]	*P* = 0.13	8.08 [5.94–11.56]	9.61 [6.75–11.62]	*P* = 0.40	*P* = 0.81
sTfR/log Ferritin Index	3.89 [3.26–5.99]	4.02 [3.50–6.76]	*P* < 0.05	4.99 [3.81–6.91]	5.72 [3.51–8.20]	*P* = 0.14	*P* = 0.73
Inflammation-associated parameters							
CRP *(mg/L)*	2.85 [1.05–5.75]	2.20 [0.60–5.00]	*P* = 0.48	2.60 [1.10–5.50]	2.30 [0.95–6.00]	*P* = 0.22	*P* = 0.73
ESR *(mm/hour)*	14.50 [6.00–43.00]	15.50 [6.00–30.25]	*P* = 0.81	16.00 [8.50–36.50]	13.00 [7.75–34.50]	*P* < 0.05	*P* = 0.10
Leukocytes *(x 10^9/L)*	7.70 [5.70–9.15]	6.50 [5.20–7.80]	*P* < 0.05	7.70 [6.00–9.60]	6.30 [5.30–7.20]	***P* < 0.01**	*P* = 0.40
Neutrophils *(x 10^9/L)*	5.11 [3.48–7.78]	4.08 [2.66–5.14]	*P* < 0.01	5.17 [4.05–7.64]	4.22 [3.14–4.68]	***P* < 0.01**	*P* = 0.47
Platelets *(x 10^9/L)*	301.00 [246.25–352.25]	268.00 [226.00–313.00]	*P* = 0.52	270.00 [234.00–349.00]	265.00 [244.25–338.25]	*P* = 0.63	*P* = 0.90
cFGF-23 *(pmol/L)*	0.86 [0.40–1.31]	1.04 [0.54–1.34]	*P* = 0.99	0.89 [0.37–1.39]	1.31 [0.57–1.65]	*P* = 0.14	*P* = 0.20
iFGF-23 *(pg/mL)*	10.12 [7.70–14.84]	9.77 [7.95–13.50]	*P* = 0.38	10.63 [6.95–13.60]	10.28 [6.59–13.73]	*P* = 0.65	*P* = 0.38
c/iFGF-23 ratio	0.06 [0.03–0.17]	0.08 [0.04–0.15]	*P* = 0.20	0.10 [0.04–0.16]	0.10 [0.06–0.19]	*P* = 0.76	*P* = 0.43
IL-1β *(pg/mL)*	0.46 [0.07–1.18]	0.89 [0.34–1.27]	*P* = 0.64	0.86 [0.22–1.28]	1.15 [0.71–1.40]	*P* = 0.72	*P* = 0.95
IL-6 *(pg/mL)*	1.79 [0.77–5.02]	1.42 [1.00–3.82]	*P* = 0.43	1.67 [0.78–4.43]	1.48 [1.04–2.89]	*P* = 0.25	*P* = 0.57
IL-10 *(pg/mL)*	0.96 [0.62–1.57]	0.87 [0.63–1.52]	*P* = 0.53	1.05 [0.51–1.54]	0.77 [0.42–1.75]	*P* = 0.73	*P* = 0.70
IL-22 *(pg/mL)*	1.23 [0.92–1.73]	0.86 [0.66–1.42]	***P* < 0.01**	1.37 [0.71–2.42]	0.97 [0.65–1.73]	*P* = 0.71	*P* < 0.05
IL-23 *(pg/mL)*	0.95 [0.46–7.38]	1.71 [0.27–7.91]	*P* = 0.94	7.62 [0.84–12.37]	6.56 [0.78–8.03]	*P* < 0.05	*P* < 0.05
TNFα *(pg/mL)*	2.17 [1.81–3.14]	2.31 [1.53–3.18]	*P* = 0.85	1.88 [1.36–3.20]	1.84 [0.92–3.14]	*P* = 0.20	*P* = 0.40
INF-γ *(pg/mL)*	14.15 [7.84–23.15]	13.41 [8.42–23.91]	*P* = 0.67	15.61 [7.73–25.06]	14.55 [4.68–34.50]	*P* = 0.93	*P* = 0.94
R-SH *(uM)*	228.62 [189.72–254.56]	227.90 [191.39–287.93]	*P* = 0.89	212.39 [180.05–263.40]	224.69 [184.23–263.88]	*P* = 0.12	*P* = 0.42
FCP *(mg/kg) ‡*	885.50 [196.75–1925.25]	113.50 [40.75–602.75]	*P* < 0.01	830.00 [255.00–1650.00]	150.00 [41.00–685.00]	*P* < 0.05	*P* = 0.57
Erythropoiesis or hypoxia-associated parameters							
EPO *(pg/mL)*	80.73 [55.44–129.74]	89.85 [62.75–131.18]	*P* = 0.83	83.98 [63.33–130.10]	90.87 [59.04–149.08]	*P* = 0.65	*P* = 0.59
MIP-3α *(pg/mL)*	25.38 [14.00–33.61]	20.52 [13.71–28.30]	*P* = 0.14	16.70 [7.95–20.68]	15.34 [8.23–31.51]	*P* = 0.78	*P* = 0.28
VEGF-A *(pg/mL)*	143.04 [80.51–215.07]	114.05 [76.13–199.89]	*P* = 0.35	115.60 [73.00–183.84]	113.36 [64.76–189.15]	*P* = 0.84	*P* = 0.50
Other parameters							
MCV *(fL)*	90.35 [86.78–94.63]	90.80 [86.10–95.10]	*P* = 0.63	92.20 [87.25–94.85]	90.90 [88.85–94.68]	*P* = 0.76	*P* = 0.82
LDH *(U/L)*	170.00 [146.50–205.25]	197.00 [163.50–253.25]	*P* = 0.55	189.00 [155.50–222.00]	198.00 [169.00–278.50]	*P* = 0.12	*P* = 0.47
Albumin *(g/L)*	41.00 [39.50–43.00]	41.50 [40.00–44.00]	*P* = 0.61	41.00 [39.00–43.00]	42.00 [39.50–44.00]	*P* = 0.05	*P* = 0.49

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. 'Montreal E3' includes patients with pancolitis. 'Montreal E1 and E2' includes patients with distal or left-sided colitis. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10:

*Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 15. Changes in biochemical parameters in patients with Crohn's disease over the course of induction therapy with either infliximab or vedolizumab, stratified by involvement of the terminal ileum.

	Terminal ileum Involvement baseline (n = 59)	Terminal ileum Involvement week 6 (n = 58)	Paired analysis	No terminal ileum involvement baseline (n = 7)	No terminal ileum Involvement week 6 (n = 7)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**8.10 [7.40–8.50]**	**8.10 [7.50–8.90]**	***P* < 0.05**	**7.70 [6.90–8.10]**	**8.05 [6.40–8.85]**	*P* = 0.92	*P* = 0.68
Hemoglobin females	*7.77 (SD 0.78)*	*7.75 [7.33–8.48]*	*P = 0.11*	*NA*	*NA*	*NA*	*NA*
Hemoglobin males	*8.30 [7.90–9.15]*	*8.40 [8.08–9.20]*	*P < 0.05*	*7.45 [6.60–8.08]*	*NA*	*NA*	*NA*
Systemic iron status parameters							
Ferritin *(µg/L)*	45.00 [27.00–80.00]	36.00 [23.25–63.75]	***P* < 0.001**	89.00 [15.00–248.00]	76.50 [23.50–163.75]	*P* = 0.08	*P* = 0.10
Iron *(µmol/L)*	11.05 [7.75–15.98]	13.95 [9.40–19.00]	*P* = 0.10	10.00 [6.00–14.00]	13.35 [8.18–17.50]	*P* = 0.34	*P* = 0.68
Transferrin *(g/L)*	2.50 [2.20–2.90]	2.70 [2.40–3.15]	***P* < 0.001**	2.30 [2.00–2.40]	2.25 [2.10–2.50]	*P* = 0.34	*P* = 0.77
TIBC *(µmol/L)*	63.50 [55.00–73.00]	66.50 [60.00–78.25]	***P* < 0.001**	57.00 [50.00–61.00]	56.00 [53.00–62.00]	*P* = 0.50	*P* = 0.72
TSAT *(%)*	17.50 [12.00–27.00]	19.50 [13.75–28.00]	*P* = 0.33	19.00 [8.75–27.50]	22.00 [10.00–28.00]	*P* = 0.12	*P* = 0.47
Hepcidin *(ng/mL)*	20.60 [7.95–39.65]	9.01 [3.11–21.27]	***P* < 0.01**	21.19 [8.11–55.91]	18.22 [0.87–53.33]	*P < 0.05*	*P* = 0.82
sTfR *(µg/mL)*	7.64 [6.23–10.02]	7.23 [6.09–9.04]	*P* = 0.67	5.72 [5.46–7.60]	7.05 [4.84–7.77]	*P* = 1.00	*P* = 0.90
sTfR/log Ferritin Index	4.73 [3.58–5.82]	4.73 [3.46–6.52]	*P* = 0.27	3.48 [2.32–5.99]	3.56 [2.81–5.45]	*P* = 0.60	*P* = 0.81
Inflammation-associated parameters							
CRP *(mg/L)*	4.55 [1.60–12.25]	1.60 [0.88–6.00]	***P* < 0.001**	10.00 [5.20–35.00]	4.15 [2.48–15.75]	*P < 0.05*	*P* = 0.13
ESR *(mm/hour)*	18.00 [9.00–35.00]	12.00 [4.00–23.50]	***P* < 0.001**	46.00 [13.00–69.25]	14.00 [3.50–64.50]	*P* = 0.14	*P* = 0.44
WBC *(x 10^9/L)*	8.00 [6.20–10.60]	6.60 [5.08–8.00]	***P* < 0.01**	6.80 [5.80–10.70]	7.00 [4.35–8.63]	*P < 0.05*	*P* = 0.26
Neutrophils *(x 10^9/L)*	5.15 [4.00–7.52]	4.01 [3.04–5.77]	***P* < 0.001**	4.61 [3.94–8.27]	4.59 [3.60–6.45]	*P* = 0.08	*P* = 0.36
Platelets *(x 10^9/L)*	327.00 [259.50–383.00]	288.50 [244.75–359.50]	***P* < 0.001**	391.00 [212.00–481.00]	261.50 [204.25–420.75]	*P* = 0.60	*P* = 0.99
cFGF-23 *(pmol/L)*	0.91 [0.57–1.59]	0.86 [0.40–1.78]	*P* = 0.54	0.76 [0.44–1.12]	0.64 [0.51–1.17]	*P* = 0.61	*P* = 0.57
iFGF-23 *(pg/mL)*	9.80 [6.47–12.69]	8.08 [5.47–11.18]	*P* = 0.44	13.89 [11.51–15.86]	8.11 [7.09–11.10]	*P < 0.05*	*P < 0.05*
c/iFGF-23 ratio	0.10 [0.06–0.16]	0.13 [0.05–0.19]	*P* = 0.32	0.05 [0.04–0.06]	0.07 [0.06–0.09]	*P* = 0.18	*P* = 0.54
IL-1β *(pg/mL)*	1.21 [0.84–1.29]	1.13 [0.71–1.30]	*P* = 0.46	1.25 [0.99–1.41]	1.08 [0.99–1.33]	*P* = 0.06	*P* = 0.25
IL-6 *(pg/mL)*	2.38 [1.28–3.52]	1.81 [1.02–2.70]	*P < 0.05*	2.66 [1.90–2.87]	2.02 [1.02–2.16]	*P* = 0.31	*P* = 0.65
IL-10 *(pg/mL)*	0.75 [0.38–1.53]	1.01 [0.47–1.65]	***P* < 0.01**	1.56 [1.42–1.68]	1.78 [1.56–2.07]	*P < 0.05*	*P* = 0.21
IL-22 *(pg/mL)*	1.10 [0.64–1.97]	0.97 [0.53–1.26]	***P* < 0.01**	1.39 [1.10–3.03]	1.48 [0.86–4.17]	*P* = 1.00	*P* = 0.38
IL-23 *(pg/mL)*	7.14 [6.00–7.90]	7.12 [5.76–8.81]	*P* = 0.05	6.76 [6.38–7.71]	8.42 [6.49–9.16]	*P* = 0.35	*P* = 0.84
TNFα *(pg/mL)*	2.08 [1.54–2.41]	1.72 [0.88–2.10]	***P* < 0.001**	3.13 [2.61–5.62]	2.42 [2.01–4.73]	*P* = 0.24	*P* = 0.48
INF-γ *(pg/mL)*	23.18 [8.53–45.42]	17.06 [6.56–31.80]	*P* = 0.06	22.95 [9.75–25.91]	17.81 [9.42–45.05]	*P* = 0.40	*P* = 0.94
R-SH *(uM)*	245.08 (SD 56.27)	235.29 [211.86–296.35]	*P* = 0.34	268.67 [246.77–282.77]	290.33 [166.23–312.55]	*P* = 1.00	*P* = 0.98
FCP *(mg/kg) ‡*	667.00 [288.25–2067.50]	157.50 [46.00–1437.50]	*P* = 0.20	*NA*	147.50 [108.75–5946.25]	*NA*	*NA*
Hypoxia-associated parameters							
EPO *(pg/mL)*	76.72 [49.46–119.09]	64.47 [49.46–97.05]	*P* = 0.06	101.53 [59.52–182.80]	65.37 [41.65–141.78]	*P* = 0.50	*P* = 0.88
MIP-3α *(pg/mL)*	19.94 [12.41–33.71]	17.16 [9.22–26.72]	*P < 0.05*	19.36 [15.78–27.77]	15.52 [14.11–19.85]	*P < 0.05*	*P* = 0.92
VEGF-A *(pg/mL)*	115.35 [77.56–225.89]	114.75 [63.52–170.19]	*P < 0.05*	125.30 [67.45–296.30]	110.87 [57.19–325.39]	*P* = 0.18	*P* = 0.74
Other parameters							
MCV *(fL)*	89.19 (SD 5.25)	89.60 (SD 5.21)	*P* = 0.15	89.00 [82.50–93.70]	89.70 [84.80–94.93]	*P* = 0.25	*P* = 0.48
LDH *(U/L)*	159.00 [135.00–206.00]	158.50 [129.25–196.50]	*P* = 0.47	197.00 [123.00–263.00]	166.50 [124.00–298.75]	*P* = 0.60	*P* = 0.93
Albumin *(g/L)*	42.00 [39.75–44.00]	43.00 [41.00–44.00]	*P < 0.05*	40.00 [38.00–42.00]	41.00 [37.75–42.50]	*P* = 0.89	*P* = 0.35

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. 'Terminal ileum involvement' includes patients with Montreal L1 or L3 classification. 'No terminal ileum involvement' includes patients with ulcerative colitis, IBD-unclassified, and Montreal L2 classified Crohn's disease. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cells,

*TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 16. Changes in biochemical parameters in patients with Crohn's disease undergoing induction therapy with either infliximab or vedolizumab.

	Infliximab baseline (n = 54)	Infliximab week 6 (n = 54)	Paired analysis	Vedolizumab baseline (n = 12)	Vedolizumab week 6 (n = 11)	Paired analysis	Δ difference between biologicals
Hemoglobin ***(mmol/L)***	**8.00 (SD 0.84)**	**8.20 [7.55–8.80]**	***P* < 0.05**	**7.80 [7.23–8.53]**	**8.00 [7.40–8.90]**	*P* = 0.65	*P* = 0.43
Hemoglobin females	*7.80 [7.20–8.40]*	*7.70 [7.30–8.50]*	*P = 0.26*	*7.70 [7.25–8.45]*	*7.75 [7.40–8.68]*	*P = 0.45*	*P = 0.93*
Hemoglobin males	*8.25 [7.85–9.13]*	*8.45 [8.10–9.23]*	***P* < 0.05**	*NA*	*NA*	*NA*	*NA*
Systemic iron status parameters							
Ferritin *(µg/L)*	44.00 [22.50–91.75]	36.00 [22.50–73.00]	***P* < 0.001**	60.50 [29.75–81.50]	37.00 [33.00–63.00]	*P* = 0.18	*P* = 0.65
Iron *(µmol/L)*	12.80 [7.80–16.60]	14.00 [11.50–19.40]	*P* = 0.06	8.75 [4.68–10.40]	9.20 [6.00–15.40]	*P* = 0.97	*P* = 0.48
Transferrin *(g/L)*	2.50 [2.20–2.90]	2.60 [2.30–3.10]	***P* < 0.001**	2.45 [2.20–2.90]	2.50 [2.40–3.00]	*P* < 0.05	*P* = 0.44
TIBC *(µmol/L)*	62.00 [55.00–73.00]	66.00 [57.00–77.50]	***P* < 0.001**	62.00 [55.00–73.00]	62.00 [60.00–77.00]	*P* = 0.06	*P* = 0.58
TSAT *(%)*	19.50 [12.25–27.00]	21.50 [14.75–28.25]	*P* = 0.18	13.00 [9.00–18.00]	13.00 [8.00–22.00]	*P* = 0.72	*P* = 0.49
Hepcidin *(ng/mL)*	17.54 [7.70–42.18]	7.91 [2.22–21.01]	***P* < 0.001**	21.55 [10.06–27.40]	16.59 [9.01–27.01]	*P* = 0.18	*P* = 0.64
sTfR *(µg/mL)*	7.66 [5.97–10.15]	7.18 [6.01–8.89]	*P* = 0.25	6.99 [5.66–7.65]	7.32 [6.67–8.98]	*P* = 0.11	*P* = 0.06
sTfR/log Ferritin Index	4.70 [3.51–6.10]	4.45 [3.32–6.39]	*P* = 0.74	4.18 [2.56–5.19]	5.25 [3.24–6.20]	*P* = 0.11	*P* = 0.12
Inflammation-associated parameters							
CRP *(mg/L)*	5.20 [1.75–12.50]	1.60 [0.55–4.60]	***P* < 0.001**	7.60 [1.80–21.50]	6.00 [1.80–14.00]	*P* = 0.29	*P* = 0.36
ESR *(mm/hour)*	17.00 [9.00–34.00]	9.00 [3.00–20.00]	***P* < 0.001**	36.50 [15.00–65.25]	33.00 [13.00–46.00]	*P* = 0.51	*P* = 0.09
WBC *(x 10^9/L)*	7.65 [5.95–9.93]	6.50 [4.60–7.90]	***P* < 0.001**	8.00 [6.35–12.13]	8.00 [6.00–14.00]	*P* = 0.72	*P* = 0.05
Neutrophils *(x 10^9/L)*	5.39 [4.03–7.34]	4.01 [2.92–4.93]	***P* < 0.001**	4.97 [3.55–9.10]	6.28 [3.15–9.49]	*P* = 0.66	*P* < 0.05
Platelets *(x 10^9/L)*	327.00 [257.00–385.00]	286.00 [240.50–356.50]	***P* < 0.001**	327.00 [223.00–409.00]	288.00 [267.00–389.00]	*P* = 0.77	*P* < 0.05
cFGF-23 *(pmol/L)*	1.03 [0.58–1.56]	0.91 [0.46–1.80]	*P* = 0.35	0.74 [0.45–0.98]	0.59 [0.25–0.82]	*P* = 0.21	*P* = 0.21
iFGF-23 *(pg/mL)*	10.34 [6.34–13.24]	8.03 [5.22–11.26]	*P* = 0.14	9.77 [7.82–13.70]	8.21 [6.87–10.28]	*P* = 0.21	*P* = 0.90
c/iFGF-23 ratio	0.10 [0.05–0.17]	0.12 [0.06–0.22]	*P* = 0.16	0.08 [0.05–0.10]	0.04 [0.03–0.14]	*P* = 0.79	*P* = 0.50
IL-1β *(pg/mL)*	1.23 [1.09–1.33]	1.16 [0.91–1.33]	*P* = 0.12	0.65 [0.18–1.39]	0.88 [0.26–1.36]	*P* = 1.00	*P* = 0.53
IL-6 *(pg/mL)*	2.53 [1.45–3.21]	1.62 [1.00–2.36]	***P* < 0.01**	2.13 [1.29–5.81]	2.66 [1.98–4.26]	*P* = 0.33	*P* = 0.05
IL-10 *(pg/mL)*	1.21 [0.39–1.57]	1.45 [0.46–1.78]	***P* < 0.01**	0.53 [0.48–1.04]	0.65 [0.48–1.57]	*P* = 0.05	*P* = 0.96
IL-22 *(pg/mL)*	1.12 [0.63–1.65]	1.00 [0.53–1.26]	***P* < 0.01**	1.78 [0.75–3.32]	1.04 [0.95–3.39]	*P* = 0.37	*P* = 0.90
IL-23 *(pg/mL)*	7.40 [6.74–7.91]	7.38 [6.53–8.94]	*P* = 0.11	1.49 [0.29–6.11]	4.30 [0.06–8.66]	*P* = 0.08	*P* = 0.45
TNFα *(pg/mL)*	2.16 [1.54–2.55]	1.64 [0.79–2.29]	***P* < 0.001**	2.08 [1.92–2.53]	2.05 [1.99–2.77]	*P* = 0.79	*P* < 0.01
INF-γ *(pg/mL)*	22.95 [9.08–37.52]	16.34 [6.56–28.78]	*P* = 0.08	23.22 [7.87–88.01]	28.19 [10.64–71.29]	*P* = 0.29	*P* = 0.67
R-SH *(uM)*	246.11 [208.25–285.26]	244.66 [211.86–300.94]	*P* = 0.31	231.67 [210.54–286.27]	223.73 [204.91–280.41]	*P* = 0.93	*P* = 0.76
FCP *(mg/kg) ‡*	772.50 [280.00–2347.50]	120.00 [40.00–185.00]	*P* = 0.50	337.50 [164.50–2097.25]	850.00 [110.00–2170.00]	*P* = 1.00	*P* = 0.47
Hypoxia-associated parameters							
EPO *(pg/mL)*	86.00 [50.59–147.16]	64.47 [45.10–118.29]	***P* < 0.01**	56.77 [40.06–76.48]	66.45 [54.02–88.42]	*P* = 0.11	*P* < 0.05
MIP-3α *(pg/mL)*	19.36 [11.73–28.90]	16.30 [9.22–23.36]	***P* < 0.01**	27.23 [20.20–49.48]	17.77 [11.49–63.59]	*P* = 0.77	*P* = 0.77
VEGF-A *(pg/mL)*	112.87 [74.50–230.24]	106.68 [61.34–170.19]	***P* < 0.05**	126.07 [88.70–229.48]	146.30 [73.53–225.93]	*P* = 0.93	*P* = 0.15
Other parameters							
MCV *(fL)*	89.50 [84.95–93.00]	90.30 [85.30–93.35]	***P* < 0.05**	90.70 [85.40–93.20]	89.60 [87.30–91.40]	*P* = 0.88	*P* = 0.63
LDH *(U/L)*	157.00 [134.00–204.00]	165.50 [137.75–199.75]	*P* = 0.14	172.00 [136.00–229.00]	130.50 [121.25–165.50]	*P* < 0.05	*P* < 0.05
Albumin *(g/L)*	42.00 [40.00–44.00]	42.50 [41.00–44.00]	*P* < 0.05	40.00 [38.25–42.75]	41.50 [39.25–43.00]	*P* = 0.77	*P* = 0.54

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell counts, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23,

*sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin, MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 17. Changes in biochemical parameters in patients with ulcerative colitis undergoing induction therapy with either infliximab or vedolizumab.

	Infliximab baseline (n = 17)	Infliximab week 6 (n = 17)	Paired analysis	Vedolizumab baseline (n = 39)	Vedolizumab week 6 (n = 37)	Paired analysis	Δ difference between biologicals
Hemoglobin *(mmol/L)*	**7.90 [7.25–8.55]**	**8.00 [7.65–8.60]**	*P* = 0.30	**8.30 [7.80–9.00]**	**8.00 [7.70–8.70]**	*P* = 0.88	*P* = 0.32
Hemoglobin females	*7.50 [7.23–8.00]*	*7.35 [6.60–7.95]*	*P = 0.20*	*7.75 [7.50–8.33]*	*7.75 [7.58–8.03]*	*P = 0.72*	*P = 0.22*
Hemoglobin males	*8.20 [7.30–8.65]*	*8.50 [7.75–8.65]*	*P = 0.08*	*8.50 [7.95–9.35]*	*8.60 [7.95–9.45]*	*P = 0.57*	*P = 0.11*
Systemic iron status parameters							
Ferritin *(µg/L)*	53.00 [24.50–120.50]	42.00 [18.00–77.50]	*P* < 0.01	40.00 [24.00–80.00]	33.00 [23.00–77.25]	*P* = 0.13	*P* = 0.13
Iron *(µmol/L)*	16.00 [10.50–19.50]	15.00 [10.30–20.00]	*P* = 0.96	12.90 [9.00–18.00]	13.25 [9.40–17.75]	*P* = 0.73	*P* = 0.80
Transferrin *(g/L)*	2.40 [2.30–2.60]	2.40 [2.20–2.70]	*P* = 0.65	2.40 [2.20–2.60]	2.55 [2.30–2.80]	***P* < 0.01**	*P* = 0.14
TIBC *(µmol/L)*	58.00 [56.50–64.50]	59.00 [54.50–68.00]	*P* = 0.80	61.00 [56.00–67.00]	64.50 [58.00–70.75]	***P* < 0.05**	*P* = 0.15
TSAT *(%)*	27.00 [18.00–37.00]	27.91 [17.50–31.50]	*P* = 0.78	19.00 [15.00–30.00]	21.00 [13.00–28.00]	*P* = 0.47	*P* = 0.88
Hepcidin *(ng/mL)*	10.51 [4.33–26.60]	7.46 [2.25–15.72]	*P* = 0.12	10.09 [3.08–20.53]	11.61 [4.73–22.85]	*P* = 0.59	*P* = 0.50
sTfR *(µg/mL)*	8.08 [6.47–11.74]	6.86 [5.94–10.71]	*P* < 0.05	7.19 [5.26–9.97]	8.46 [6.68–11.10]	***P* < 0.01**	***P* < 0.01**
sTfR/log Ferritin Index	4.48 [3.51–7.87]	4.33 [3.50–6.83]	*P* = 0.80	4.51 [3.09–6.52]	5.32 [3.54–8.37]	***P* < 0.01**	*P* < 0.05
Inflammation-associated parameters							
CRP *(mg/L)*	4.50 [2.00–14.00]	1.00 [0.55–5.00]	*P* < 0.01	2.40 [0.90–5.00]	2.65 [1.20–5.00]	*P* = 0.64	***P* < 0.01**
ESR *(mm/hour)*	35.00 [8.50–46.50]	12.00 [7.00–32.00]	*P* < 0.01	13.00 [6.00–28.00]	14.00 [6.00–30.25]	*P* = 0.95	*P* < 0.05
WBC *(x 10^9/L)*	7.40 [5.90–8.50]	5.30 [4.05–6.80]	*P* < 0.01	8.00 [5.70–10.30]	6.65 [5.55–7.88]	***P* < 0.01**	*P* = 0.69
Neutrophils *(x 10^9/L)*	5.07 [3.14–6.00]	2.95 [2.21–4.92]	*P* < 0.05	5.25 [3.76–7.88]	4.27 [3.37–5.00]	***P* < 0.001**	*P* = 0.71
Platelets *(x 10^9/L)*	264.00 [248.00–303.00]	258.00 [230.00–283.00]	*P* = 0.18	302.00 [239.00–357.00]	289.00 [230.00–337.00]	*P* = 0.68	*P* = 0.40
cFGF-23 *(pmol/L)*	1.21 [0.39–2.53]	1.17 [0.58–2.31]	*P* = 0.57	0.82 [0.35–1.22]	1.15 [0.54–1.55]	*P* = 0.26	*P* = 1.00
iFGF-23 *(pg/mL)*	8.95 [4.41–17.32]	6.91 [4.32–13.65]	*P* = 0.85	10.90 [7.78–14.64]	9.93 [8.27–13.70]	*P* = 0.82	*P* = 0.76
c/iFGF-23 ratio	0.15 [0.05–0.34]	0.10 [0.05–0.37]	*P* = 0.64	0.06 [0.04–0.12]	0.09 [0.04–0.15]	*P* = 0.68	*P* = 0.83
IL-1β *(pg/mL)*	1.31 [0.25–1.48]	1.03 [0.25–1.27]	*P* = 0.27	0.60 [0.12–1.11]	0.93 [0.41–1.36]	*P* = 0.22	*P* = 0.11
IL-6 *(pg/mL)*	0.96 [0.46–5.42]	1.03 [0.37–1.32]	*P* = 0.21	1.79 [0.99–4.54]	2.23 [1.27–3.72]	*P* = 0.43	*P* = 0.40
IL-10 *(pg/mL)*	1.14 [0.38–1.74]	0.77 [0.40–1.98]	*P* = 0.65	0.96 [0.62–1.56]	0.89 [0.59–1.53]	*P* = 0.43	*P* = 0.88
IL-22 *(pg/mL)*	1.23 [0.48–2.20]	0.94 [0.505–1.58]	*P* = 0.21	1.26 [0.91–1.75]	0.86 [0.65–1.46]	*P* < 0.05	*P* = 0.63
IL-23 *(pg/mL)*	7.38 [4.09–15.21]	7.44 [6.82–8.45]	*P* = 0.27	1.13 [0.55–8.06]	1.51 [0.31–7.76]	*P* = 0.23	*P* = 0.47
TNFα *(pg/mL)*	1.44 [0.95–3.03]	0.78 [0.53–1.73]	*P* < 0.01	2.07 [1.68–3.15]	2.71 [1.85–3.51]	*P* = 0.16	***P* < 0.001**
INF-γ *(pg/mL)*	12.09 [5.88–21.01]	12.14 [2.76–35.57]	*P* = 0.20	15.68 [8.04–25.23]	13.79 [8.13–27.17]	*P* = 0.67	*P* = 0.19
R-SH *(uM)*	210.49 [182.09–232.76]	240.86 [189.37–297.67]	*P* = 0.10	233.56 [190.12–262.21]	226.72 [181.47–264.80]	*P* = 0.90	*P* = 0.15
FCP *(mg/kg)* ‡	1835.00 [727.50–2162.50]	*NA*	*NA*	805.00 [215.00–1530.00]	138.00 [41.00–595.00]	***P* < 0.01**	*NA*
Hypoxia-associated parameters							
EPO *(pg/mL)*	88.20 [68.29–144.61]	97.86 [48.27–158.55]	*P* = 0.19	82.93 [55.73–120.38]	90.04 [65.85–135.22]	*P* = 0.41	*P* = 0.19
MIP-3α *(pg/mL)*	17.37 [9.35–26.69]	13.25 [10.69–20.47]	*P* < 0.05	20.90 [10.72–32.43]	22.10 [13.71–34.03]	*P* = 0.90	*P* = 0.09
VEGF-A *(pg/mL)*	120.09 [60.60–185.32]	89.24 [50.08–186.06]	*P* = 0.19	119.14 [80.98–190.13]	119.26 [76.42–207.80]	*P* = 0.83	*P* = 0.28
Other parameters							
MCV *(fL)*	91.80 [87.45–93.65]	90.80 [88.80–93.25]	*P* = 0.45	91.40 [87.10–94.70]	90.80 [86.10–96.10]	*P* = 0.81	*P* = 0.57
LDH *(U/L)*	183.00 [147.50–214.50]	178.50 [157.00–231.00]	*P* = 0.57	176.00 [152.00–216.50]	204.00 [168.00–268.25]	*P* = 0.19	*P* = 0.74
Albumin *(g/L)*	42.00 [38.50–43.00]	42.00 [39.00–44.00]	*P* = 0.24	41.00 [40.00–43.00]	42.00 [40.00–44.00]	*P* = 0.25	*P* = 0.99

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell counts, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin,

*MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 18. Changes in biochemical parameters in patients with Crohn's disease, stratified by adequate response at week 14 to induction therapy with either infliximab or vedolizumab.

	Responders CD baseline (n = 52)	Responders CD week 6 (n = 52)	Paired analysis	Non-responders CD baseline (n = 10)	Non-responders CD week 6 (n = 10)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**8.10 [7.40–8.50]**	**8.15 [7.53–8.90]**	***P* < 0.05**	**7.445 [6.88–8.08]**	**7.55 [6.78–8.23]**	*P* = 1.00	*P* = 0.44
Hemoglobin females	*7.83 (SD 0.74)*	*7.75 [7.33–8.58]*	*P = 0.13*	*7.20 [6.50–7.80]*	*7.40 [5.95–7.85]*	*P = 0.72*	*P = 0.41*
Hemoglobin males	*8.30 [8.10–9.20]*	*8.45 [8.13–9.20]*	*P < 0.05*	*7.90 [7.05–8.15]*	*8.00 [6.45–9.10]*	*P = 0.69*	*P = 0.75*
Systemic iron status parameters							
Ferritin *(µg/L)*	48.50 [32.00–88.00]	38.50 [25.00–65.25]	***P* < 0.001**	31.50 [17.25–143.75]	34.50 [9.75–129.50]	*P* = 0.20	*P* = 0.99
Iron *(µmol/L)*	12.00 [8.00–15.80]	14.00 [10.70–19.00]	*P* = 0.15	5.85 [3.95–11.93]	8.10 [4.55–17.23]	*P* = 0.17	*P* = 0.53
Transferrin *(g/L)*	2.45 [2.20–2.90]	2.60 [2.40–3.10]	***P* < 0.001**	2.55 [2.28–2.93]	2.70 [2.18–3.20]	*P* = 0.15	*P* = 0.80
TIBC *(µmol/L)*	61.00 [55.00–73.00]	64.50 [60.00–76.50]	***P* < 0.001**	64.50 [56.25–73.75]	67.50 [54.50–81.25]	*P* = 0.15	*P* = 0.81
TSAT *(%)*	18.00 [13.00–27.00]	20.71 [15.00–28.75]	*P* = 0.37	10.00 [5.75–19.00]	10.50 [6.50–25.75]	*P* = 0.24	*P* = 0.63
Hepcidin *(ng/mL)*	20.90 [9.02–41.21]	8.71 [2.62–21.07]	***P* < 0.001**	15.66 [5.86–43.71]	10.08 [4.02–54.82]	*P* = 0.59	*P* = 0.32
sTfR *(µg/mL)*	7.57 [5.96–9.65]	7.14 [5.72–8.49]	*P* = 0.24	7.08 [5.81–11.10]	7.79 [6.50–11.34]	*P* = 0.24	*P* = 0.10
sTfR/log Ferritin Index	4.62 [3.53–5.80]	4.50 [3.31–5.97]	*P* = 0.63	4.84 [2.74–9.42]	5.93 [3.11–10.29]	*P* = 0.17	*P* = 0.11
Inflammation-associated parameters							
CRP *(mg/L)*	4.50 [1.50–12.00]	1.60 [0.83–4.60]	***P* < 0.001**	16.15 [3.70–41.25]	12.00 [1.43–15.50]	*P < 0.05*	*P* = 0.16
ESR *(mm/hour)*	16.00 [9.00–33.00]	11.00 [3.75–20.50]	***P* < 0.001**	36.50 [21.75–68.75]	30.50 [16.25–45.00]	*P* = 0.14	*P* = 0.98
WBC *(x 10^9/L)*	7.25 [5.70–10.18]	6.40 [4.60–7.90]	***P* < 0.01**	10.00 [7.78–11.80]	7.95 [6.88–10.90]	*P* = 0.11	*P* = 0.68
Neutrophils *(x 10^9/L)*	5.06 [3.68–7.37]	3.98 [2.89–5.06]	***P* < 0.01**	7.46 [5.36–9.25]	5.48 [4.03–8.05]	*P* = 0.14	*P* = 0.72
Platelets *(x 10^9/L)*	311.50 [252.75–381.00]	278.50 [238.75–331.00]	***P* < 0.001**	386.70 (SD 105.45)	376.00 [277.75–475.75]	*P* = 0.64	*P* = 0.17
cFGF-23 *(pmol/L)*	0.84 [0.48–1.37]	0.82 [0.41–1.56]	*P* = 0.69	1.22 [0.71–1.99]	1.42 [0.33–1.78]	*P* = 0.88	*P* = 0.87
iFGF-23 *(pg/mL)*	9.77 [6.20–13.10]	7.83 [5.41–10.92]	*P* = 0.35	10.67 [8.37–13.24]	8.56 [7.75–13.86]	*P* = 0.24	*P* = 0.66
c/iFGF-23 ratio	0.10 [0.05–0.15]	0.12 [0.05–0.19]	*P* = 0.13	0.08 [0.06–0.19]	0.09 [0.04–0.19]	*P* = 0.39	*P* = 0.14
IL-1β *(pg/mL)*	1.22 [1.01–1.29]	1.13 [0.88–1.30]	*P* = 0.09	0.99 [0.38–1.47]	1.20 [0.21–1.32]	*P* = 0.72	*P* = 0.95
IL-6 *(pg/mL)*	2.43 [1.52–3.44]	1.71 [1.00–2.70]	***P* < 0.05**	2.74 [1.17–5.93]	2.20 [1.27–3.85]	*P* = 0.52	*P* = 0.93
IL-10 *(pg/mL)*	1.17 [0.38–1.57]	1.43 [0.47–1.76]	***P* < 0.01**	0.57 [0.50–1.28]	0.64 [0.46–1.58]	*P* = 0.11	*P* = 0.78
IL-22 *(pg/mL)*	1.11 [0.61–1.77]	0.96 [0.51–1.26]	***P* < 0.05**	2.01 [1.08–3.48]	1.08 [1.02–2.90]	*P* = 0.20	*P* = 0.58
IL-23 *(pg/mL)*	7.40 [6.45–8.14]	7.38 [5.87–8.94]	*P* = 0.10	6.00 [1.44–7.06]	*NA*	*NA*	*NA*
TNFα *(pg/mL)*	2.13 [1.65–2.52]	1.69 [0.90–2.10]	***P* < 0.001**	1.78 [1.40–2.22]	2.01 [1.09–4.40]	*P* = 0.65	*P < 0.05*
INF-γ *(pg/mL)*	22.95 [8.21–44.57]	16.34 [6.83–30.37]	*P < 0.05*	22.74 [11.21–105.00]	31.86 [7.62–74.55]	*P* = 0.72	*P* = 0.69
R-SH *(uM)*	244.88 [207.02–283.16]	244.66 [211.41–298.87]	*P* = 0.10	231.67 [214.42–291.45]	213.35 [168.89–243.46]	*P < 0.05*	*P < 0.01*
FCP *(mg/kg) ‡*	615.00 [216.25–2067.50]	117.50 [42.00–190.00]	*P* = 0.13	724.50 [377.50–2875.00]	2170.00 [360.00–4037.50]	*P* = 0.50	*P* = 0.22
Hypoxia-associated parameters							
EPO *(pg/mL)*	77.60 [49.05–118.86]	64.47 [45.35–94.74]	***P* < 0.05**	76.58 [47.50–184.06]	73.76 [42.74–146.33]	*P* = 0.80	*P* = 0.20
MIP-3α *(pg/mL)*	20.04 [10.96–33.99]	16.44 [8.77–28.23]	***P* < 0.05**	19.82 [16.35–27.50]	16.30 [12.36–20.34]	*P* = 0.33	*P* = 0.67
VEGF-A *(pg/mL)*	117.96 [69.80–237.29]	116.55 [62.27–167.55]	*P* = 0.10	98.01 [71.21–244.88]	96.82 [51.55–240.67]	*P* = 0.39	*P* = 0.72
Other parameters							
MCV *(fL)*	89.65 [85.08–92.85]	90.15 [86.08–93.38]	*P < 0.05*	90.60 [82.30–93.30]	87.80 [84.80–90.83]	*P* = 0.96	*P* = 0.84
LDH *(U/L)*	159.00 [134.00–207.00]	160.50 [135.25–199.25]	*P* = 0.38	163.00 [143.50–217.50]	145.00 [120.25–175.25]	*P* = 0.86	*P* = 0.51
Albumin *(g/L)*	41.00 [40.00–44.00]	43.00 [41.00–44.00]	*P < 0.05*	38.50 [37.50–44.00]	41.50 [36.25–43.25]	*P* = 0.59	*P* = 0.18

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin,

*MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 19. Changes in biochemical parameters in patients with ulcerative colitis, stratified by adequate (non-)response at week 14 to induction therapy with either infliximab or vedolizumab.

	Responders UC baseline (n = 40)	Responders UC week 6 (n = 40)	Paired analysis	Non-responders UC baseline (n = 13)	Non-responders UC week 6 (n = 12)	Paired analysis	Δ difference between groups
Hemoglobin ***(mmol/L)***	**8.19 (SD 0.91)**	**8.00 [7.70–8.70]**	*P* = 0.58	**8.20 [7.80–8.45]**	**8.25 [7.90–8.50]**	*P* = 0.44	*P* = 0.55
Hemoglobin females	*7.65 [7.28–8.03]*	*7.75 [6.98–8.00]*	*P = 0.34*	*NA*	*NA*	*NA*	*NA*
Hemoglobin males	*8.52 (SD 0.86)*	*8.57 (SD 0.86)*	*P = 0.43*	*8.05 [7.43–8.40]*	*8.30 [7.90–8.50]*	*P = 0.21*	*P = 0.57*
Systemic iron status parameters							
Ferritin *(µg/L)*	46.00 [24.50–96.50]	39.50 [22.25–77.50]	*P* < 0.01	28.00 [21.00–149.00]	35.50 [23.00–90.25]	*P* = 0.58	*P* = 0.65
Iron *(µmol/L)*	14.45 [9.78–19.23]	14.95 [9.58–19.00]	*P* = 0.68	11.00 [8.00–13.85]	13.60 [8.23–15.55]	*P* = 0.64	*P* = 0.54
Transferrin *(g/L)*	2.40 [2.20–2.60]	2.50 [2.30–2.80]	*P* < 0.01	2.30 [2.10–2.68]	2.35 [2.05–2.70]	*P* = 1.00	*P* = 0.18
TIBC *(µmol/L)*	60.50 [56.25–66.00]	63.00 [58.00–70.75]	*P* < 0.05	57.00 [53.00–67.00]	58.00 [51.00–69.00]	*P* = 0.86	*P* = 0.29
TSAT *(%)*	25.50 [15.00–33.75]	21.50 [13.25–29.00]	*P* = 0.42	19.00 [13.25–26.00]	24.00 [13.00–27.00]	*P* = 0.81	*P* = 0.54
Hepcidin *(ng/mL)*	9.86 [3.31–20.40]	9.49 [3.51–25.60]	*P* = 0.34	5.49 [2.60–22.73]	12.64 [1.58–17.41]	*P* = 0.43	*P* = 0.79
sTfR *(µg/mL)*	7.47 [5.46–11.01]	8.19 [6.32–10.85]	*P* = 0.16	8.01 [6.10–10.22]	8.16 [5.70–10.85]	*P* = 0.72	*P* = 0.95
sTfR/log Ferritin Index	4.49 [3.44–6.79]	5.17 [3.53–7.59]	*P* < 0.05	4.68 [3.43–7.42]	4.63 [3.45–8.20]	*P* = 0.43	*P* = 0.49
Inflammation-associated parameters							
CRP *(mg/L)*	2.55 [0.90–5.00]	1.95 [0.60–4.68]	*P* = 0.06	4.90 [1.45–8.80]	4.25 [1.03–10.65]	*P* = 0.84	*P* = 0.43
ESR *(mm/hour)*	14.50 [6.00–37.25]	12.00 [6.00–26.00]	*P* < 0.05	23.00 [7.00–40.00]	28.50 [9.75–36.75]	*P* = 0.84	*P* = 0.21
WBC *(x 10^9/L)*	7.60 [5.73–8.80]	6.25 [5.13–7.68]	***P* < 0.001**	7.60 [5.85–10.30]	6.55 [5.45–7.25]	*P* = 0.13	*P* = 0.47
Neutrophils *(x 10^9/L)*	5.07 [3.70–7.37]	4.02 [2.69–4.98]	***P* < 0.001**	5.02 [3.72–8.04]	4.32 [2.81–5.06]	*P* = 0.14	*P* = 0.46
Platelets *(x 10^9/L)*	271.00 [239.00–320.25]	265.00 [242.00–301.00]	*P* = 0.29	293.00 [238.50–359.00]	257.00 [224.50–343.75]	*P* = 0.81	*P* = 0.62
cFGF-23 *(pmol/L)*	0.89 [0.51–1.27]	1.04 [0.49–1.63]	*P* = 0.18	1.08 [0.38–2.89]	1.29 [0.99–1.43]	*P* = 0.81	*P* = 0.71
iFGF-23 *(pg/mL)*	10.37 [7.59–14.77]	9.99 [7.63–13.75]	*P* = 0.93	9.48 [6.68–15.21]	9.33 [6.64–12.37]	*P* = 0.70	*P* = 0.63
c/iFGF-23 ratio	0.07 [0.04–0.15]	0.08 [0.04–0.15]	*P* = 0.46	0.10 [0.04–0.21]	0.12 [0.06–0.24]	*P* = 0.81	*P* = 0.91
IL-1β *(pg/mL)*	0.46 [0.12–1.24]	0.93 [0.17–1.32]	*P* = 0.72	1.07 [0.29–1.36]	1.20 [0.87–1.39]	*P* = 0.75	*P* = 0.83
IL-6 *(pg/mL)*	1.58 [0.76–4.23]	1.34 [0.98–2.35]	*P* = 0.06	2.64 [0.91–5.54]	3.67 [1.05–4.24]	*P* = 0.53	*P* = 0.16
IL-10 *(pg/mL)*	1.00 [0.62–1.58]	0.78 [0.47–1.67]	*P* = 0.21	1.26 [0.63–1.68]	0.99 [0.61–1.60]	*P* = 0.48	*P* = 0.34
IL-22 *(pg/mL)*	1.32 [0.91–2.31]	0.84 [0.65–1.57]	*P* < 0.01	0.97 [0.66–1.49]	0.92 [0.55–1.41]	*P* = 0.53	*P* = 0.18
IL-23 *(pg/mL)*	0.99 [0.55–7.68]	1.71 [0.47–7.29]	*P* = 0.12	7.87 [1.23–9.67]	7.91 [0.19–8.88]	*P* = 0.46	*P* = 1.00
TNFα *(pg/mL)*	1.91 [1.37–2.83]	1.93 [1.12–3.06]	*P* = 0.87	3.05 [1.80–4.01]	2.96 [1.11–3.16]	*P* = 0.39	*P* = 0.24
INF-γ *(pg/mL)*	15.41 [8.83–24.70]	13.77 [7.43–34.22]	*P* = 0.73	10.76 [4.86–24.26]	13.68 [11.66–22.31	*P* = 0.89	*P* = 0.89
R-SH *(uM)*	216.54 [189.68–257.83]	233.41 [187.45–289.22]	*P* = 0.16	191.43 [180.05–240.05]	209.96 [181.71–238.08]	*P* = 0.94	*P* = 0.53
FCP *(mg/kg) ‡*	913.00 [255.00–1741.75]	138.00 [40.50–258.50]	***P* < 0.01**	855.00 [682.50–2497.50]	*NA*	*NA*	*NA*
Hypoxia-associated parameters							
EPO *(pg/mL)*	91.82 [72.37–141.51]	92.23 [60.98–155.56]	*P* = 0.60	70.29 [56.05–92.93]	90.68 [56.74–119.82]	*P* = 0.18	*P* = 0.14
MIP-3α *(pg/mL)*	17.56 [8.43–29.91]	15.56 [12.41–27.16]	*P* = 0.27	21.66 [17.44–34.70]	22.16 [13.16–33.21]	*P* = 0.81	*P* = 0.37
VEGF-A *(pg/mL)*	117.84 [73.15–171.75]	104.72 [69.24–190.52]	*P* = 0.46	119.14 [78.45–209.95]	119.26 [63.25–195.89]	*P* = 0.94	*P* = 0.63
Other parameters							
MCV *(fL)*	91.20 [87.13–95.65]	90.50 [87.90–94.70]	*P* = 0.21	90.10 [82.85–92.55]	92.10 [84.38–94.15]	*P* = 0.58	*P* = 0.30
LDH *(U/L)*	179.00 [158.75–205.25]	197.00 [168.25–249.25]	*P* = 0.06	176.00 [141.00–297.00]	198.00 [143.00–347.00]	*P* = 0.59	*P* = 0.31
Albumin *(g/L)*	42.00 [40.00–43.00]	42.50 [40.00–44.00]	*P* < 0.05	40.00 [38.50–43.00]	41.00 [39.00–42.00]	*P* = 0.92	*P* = 0.28

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin,

*MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 20. Changes in biochemical parameters in patients with IBD responding to induction therapy with either infliximab or vedolizumab.

	Responders IFX baseline (n = 59)	Responders IFX week 6 (n = 59)	Paired analysis	Responders VEDO baseline (n = 33)	Responders VEDO week 6 (n = 33)	Paired analysis	Δ difference between groups
Hemoglobin *(mmol/L)*	**8.10 [7.40–08.50]**	**8.10 [7.60–8.60]**	*P* < 0.05	**8.10 [7.65–8.95]**	**8.00 [7.70–9.18]**	*P* = 0.29	*P* = 0.40
Hemoglobin females	*7.70 [7.30–8.30]*	*7.70 [7.20–8.40]*	*P = 0.52*	*7.70 [7.50–8.30]*	*7.80 [7.50–8.00]*	*P = 0.65*	*P = 0.89*
Hemoglobin males	*8.30 [7.80–9.10]*	*8.40 [8.00–9.15]*	*P < 0.05*	*8.70 [8.08–9.50]*	*8.90 [8.00–9.50]*	*P = 0.25*	*P = 0.14*
Systemic iron status parameters							
Ferritin *(µg/L)*	49.00 [32.00–97.00]	41.00 [25.00–70.00]	***P* < 0.001**	46.00 [24.00–82.50]	34.00 [23.00–71.50]	*P* < 0.05	*P* = 0.41
Iron *(µmol/L)*	14.00 [8.70–17.25]	15.32 (SD 5.82)	*P* = 0.07	13.50 [9.55–19.15]	12.90 [8.80–17.70]	*P* = 0.13	*P* < 0.05
Transferrin *(g/L)*	2.40 [2.20–2.80]	2.50 [2.30–3.00]	***P* < 0.001**	2.40 [2.20–2.65]	2.50 [2.40–2.80]	***P* < 0.01**	*P* = 1.00
TIBC *(µmol/L)*	61.00 [56.00–71.00]	64.00 [57.00–75.00]	***P* < 0.001**	60.00 [55.00–67.00]	64.00 [60.50–70.50]	***P* < 0.01**	*P* = 0.76
TSAT *(%)*	22.00 [13.00–28.00]	24.00 [16.00–31.00]	*P* = 0.16	20.00 [15.00–31.50]	19.00 [13.00–28.00]	*P* = 0.06	*P* < 0.05
Hepcidin *(ng/mL)*	15.61 [7.20–41.33]	7.91 [2.83–18.52]	***P* < 0.001**	13.01 [3.88–21.55]	11.87 [5.43–26.26]	*P* = 0.56	*P* = 0.05
sTfR *(µg/mL)*	7.77 [6.00–10.13]	7.12 [5.88–8.60]	***P* < 0.05**	7.13 [5.32–10.03]	8.59 [6.70–10.63]	***P* < 0.01**	***P* < 0.001**
sTfR/log Ferritin Index	4.68 [3.56–5.99]	4.19 [3.45–5.86]	*P* = 0.96	4.39 [2.99–6.63]	5.36 [3.57–7.48]	***P* < 0.01**	***P* < 0.01**
Inflammation-associated parameters							
CRP *(mg/L)*	4.55 [1.58–13.50]	1.60 [0.50–4.60]	***P* < 0.001**	2.30 [0.90–4.20]	2.20 [1.20–4.65]	*P* = 0.85	***P* < 0.001**
ESR *(mm/hour)*	16.00 [7.75–35.25]	9.00 [4.00–18.50]	***P* < 0.001**	13.00 [6.00–27.00]	13.50 [7.00–30.75]	*P* = 0.38	***P* < 0.01**
WBC *(x 10^9/L)*	7.30 [5.70–9.70]	6.30 [4.30–7.80]	***P* < 0.001**	8.00 [5.70–10.55]	6.70 [5.50–8.10]	*P* < 0.05	*P* = 0.38
Neutrophils *(x 10^9/L)*	5.09 [3.80–6.94]	3.49 [2.40–488]	***P* < 0.001**	4.99 [3.67–8.63]	4.31 [3.42–5.21]	***P* < 0.01**	*P* = 0.64
Platelets *(x 10^9/L)*	306.50 [259.50–376.25]	275.00 [245.00–333.00]	***P* < 0.001**	265.50 [220.00–333.75]	271.50 [227.75–300.50]	*P* = 0.72	*P* < 0.05
cFGF-23 *(pmol/L)*	0.87 [0.52–1.53]	0.88 [0.42–1.83]	*P* = 0.33	0.76 [0.48–1.19]	1.03 [0.47–1.49]	*P* = 0.46	*P* = 0.90
iFGF-23 *(pg/mL)*	9.81 [5.86–13.55]	7.56 [5.07–10.13]	*P* = 0.59	10.12 [7.70–14.71]	10.14 [8.09–13.73]	*P* = 0.74	*P* = 0.91
c/iFGF-23 ratio	0.10 [0.05–0.17]	0.11 [0.06–0.23]	*P* = 0.38	0.06 [0.04–0.11]	0.08 [0.04–0.14]	*P* = 0.97	*P* = 0.56
IL-1β *(pg/mL)*	1.23 [1.05–1.31]	1.08 [0.77–1.29]	*P* = 0.06	0.46 [0.12–1.04]	0.91 [0.26–1.34]	*P* = 0.43	*P* = 0.09
IL-6 *(pg/mL)*	2.38 [1.07–3.72]	1.46 [0.68–1.99]	***P* < 0.01**	1.71 [0.91–3.85]	1.82 [1.21–2.88]	*P* = 0.78	*P* = 0.09
IL-10 *(pg/mL)*	1.20 [0.38–1.58]	1.42 [0.44–1.78]	*P* < 0.05	0.93 [0.59–1.57]	0.83 [0.53–1.63]	*P* = 0.43	*P* < 0.05
IL-22 *(pg/mL)*	1.16 [0.60–1.97]	0.94 [0.50–1.27]	***P* = 0.002**	1.15 [0.76–1.73]	0.85 [0.66–1.54]	*P* < 0.05	*P* = 0.90
IL-23 *(pg/mL)*	7.54 [6.82–8.54]	7.38 [6.63–8.82]	*P* = 0.68	0.89 [0.42–7.21]	1.18 [0.29–7.27]	*P* = 0.88	*P* = 0.62
TNFα *(pg/mL)*	2.08 [1.33–2.53]	1.51 [0.64–2.00]	***P* < 0.001**	1.95 [1.65–2.61]	2.08 [1.74–3.30]	*P* = 0.14	***P* < 0.001**
INF-γ *(pg/mL)*	19.66 [9.66–40.11]	17.20 [6.59–32.03]	*P* = 0.32	15.55 [7.73–26.67]	13.75 [7.51–28.19]	*P* = 0.37	*P* = 0.97
R-SH *(uM)*	238.23 [191.64–274.66]	244.63 [206.05–299.12]	*P* = 0.11	216.68 [200.78–271.40]	236.64 [196.55–287.02]	*P* = 0.14	*P* = 0.91
FCP *(mg/kg) ‡*	1170.00 [276.25–2245.00]	120.00 [40.00–221.25]	*P* < 0.05	410.00 [235.00–1306.00]	115.00 [41.00–217.00]	***P* < 0.01**	*P* = 0.17
Hypoxia-associated parameters							
EPO *(pg/mL)*	83.87 [50.75–137.68]	64.16 [48.32–114.10]	***P* < 0.01**	83.98 [49.34–133.25]	74.32 [64.06–128.28]	*P* = 0.94	*P* = 0.18
MIP-3α *(pg/mL)*	18.60 [10.55–30.79]	13.98 [8.77–20.84]	***P* < 0.01**	19.23 [10.53–31.96]	22.10 [11.49–36.19]	*P* = 0.89	*P* = 0.06
VEGF-A *(pg/mL)*	120.09 [67.45–220.09]	109.18 [61.80–168.87]	*P* = 0.06	115.60 [74.03–157.80]	120.24 [73.57–217.59]	*P* = 0.71	*P* = 0.29
Other parameters							
MCV *(fL)*	89.65 [85.28–93.08]	90.30 [86.00–93.40]	*P* = 0.10	91.10 [87.13–95.65]	90.25 [88.18–95.23]	*P* = 0.39	*P* = 0.11
LDH *(U/L)*	164.00 [134.00–203.00]	168.00 [143.00–199.25]	*P* = 0.16	181.00 [159.00–227.00]	200.50 [166.50–249.25]	*P* = 0.25	*P* = 0.91
Albumin *(g/L)*	41.50 [40.00–44.00]	42.50 [41.00–44.25]	***P* < 0.05**	41.50 [40.00–43.00]	43.00 [40.00–44.00]	*P* = 0.14	*P* = 0.48

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin,

*MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 21. Changes in biochemical parameters in patients with IBD stratified by (non-)response to induction therapy with infliximab.

	Responders IFX baseline (n = 59)	Responders IFX week 6 (n = 59)	Paired analysis	Non-responders IFX baseline (n = 9)	Non-responders IFX week 6 (n = 9)	Paired analysis	Baseline difference between groups
Hemoglobin *(mmol/L)*	**8.10 [7.40–08.50]**	**8.10 [7.60–8.60]**	*P* < 0.05	**7.9 [6.60–8.25]**	**8.50 [7.55–8.80]**	*P* = 0.15	*P* = 0.22
Hemoglobin females	*7.70 [7.30–8.30]*	*7.70 [7.20–8.40]*	*P = 0.52*	*NA*	*NA*	*NA*	*NA*
Hemoglobin males	*8.30 [7.80–9.10]*	*8.40 [8.00–9.15]*	*P < 0.05*	*8.00 [7.60–8.30]*	*8.50 [7.90–8.90]*	*P = 0.06*	*P = 0.19*
Systemic iron status parameters							
Ferritin *(µg/L)*	49.00 [32.00–97.00]	41.00 [25.00–70.00]	***P* < 0.001**	22.00 [16.50–146.50]	26.00 [11.00–109.50]	*P* = 0.17	*P* = 0.61
Iron *(µmol/L)*	14.00 [8.70–17.25]	15.32 (SD 5.82)	*P* = 0.07	13.90 [5.80–19.50]	13.60 [6.00–15.40]	*P* = 0.68	*P* = 0.99
Transferrin *(g/L)*	2.40 [2.20–2.80]	2.50 [2.30–3.00]	***P* < 0.001**	2.45 [2.03–2.93]	2.40 [2.00–2.95]	*P* = 0.80	*P* = 0.81
TIBC *(µmol/L)*	61.00 [56.00–71.00]	64.00 [57.00–75.00]	***P* < 0.001**	60.00 [52.00–72.50]	59.00 [49.50–75.00]	*P* = 0.59	*P* = 0.75
TSAT *(%)*	22.00 [13.00–28.00]	24.00 [16.00–31.00]	*P* = 0.16	24.50 [9.00–36.00]	24.00 [8.50–26.00]	*P* = 0.50	*P* = 0.74
Hepcidin *(ng/mL)*	15.61 [7.20–41.33]	7.91 [2.83–18.52]	***P* < 0.001**	10.18 [5.15–31.46]	9.05 [1.68–46.37]	*P* = 0.58	*P* = 0.32
sTfR *(µg/mL)*	7.77 [6.00–10.13]	7.12 [5.88–8.60]	***P* < 0.05**	10.81 [5.93–13.58]	8.98 [5.94–13.22]	*P* = 0.95	*P* = 0.24
sTfR/log Ferritin Index	4.68 [3.56–5.99]	4.19 [3.45–5.86]	*P* = 0.96	8.18 [2.76–11.56]	7.75 [2.84–12.28]	*P* = 0.68	*P* = 0.40
Inflammation-associated parameters							
CRP *(mg/L)*	4.55 [1.58–13.50]	1.60 [0.50–4.60]	***P* < 0.001**	5.00 [2.25–20.00]	1.20 [0.80–12.00]	*P* < 0.05	*P* = 0.61
ESR *(mm/hour)*	16.00 [7.75–35.25]	9.00 [4.00–18.50]	***P* < 0.001**	35.00 [17.00–53.50]	27.00 [12.00–40.50]	*P* = 0.09	*P* = 0.07
WBC *(x 10^9/L)*	7.30 [5.70–9.70]	6.30 [4.30–7.80]	***P* < 0.001**	9.20 [7.05–10.55]	7.00 [5.90–7.95]	*P* < 0.05	*P* = 0.24
Neutrophils *(x 10^9/L)*	5.09 [3.80–6.94]	3.49 [2.40–488]	***P* < 0.001**	6.65 [5.08–8.62]	4.46 [4.02–5.57]	*P* < 0.05	*P* = 0.12
Platelets *(x 10^9/L)*	306.50 [259.50–376.25]	275.00 [245.00–333.00]	***P* < 0.001**	292.00 [231.50–401.50]	247.00 [217.00–385.00]	*P* = 0.21	*P* = 0.66
cFGF-23 *(pmol/L)*	0.87 [0.52–1.53]	0.88 [0.42–1.83]	*P* = 0.33	1.48 [0.89–4.18]	1.34 [1.11–1.79]	*P* = 0.68	*P* = 0.06
iFGF-23 *(pg/mL)*	9.81 [5.86–13.55]	7.56 [5.07–10.13]	*P* = 0.59	10.96 [6.98–18.83]	11.84 [5.00–14.14]	*P* = 0.52	*P* = 0.61
c/iFGF-23 ratio	0.10 [0.05–0.17]	0.11 [0.06–0.23]	*P* = 0.38	*0.13 [0.06–0.29]*	*0.13 [0.09–0.27]*	*P* = 0.86	*P* = 0.38
IL-1β *(pg/mL)*	1.23 [1.05–1.31]	1.08 [0.77–1.29]	*P* = 0.06	*NA*	*NA*	*NA*	*NA*
IL-6 *(pg/mL)*	2.38 [1.07–3.72]	1.46 [0.68–1.99]	***P* < 0.01**	2.23 [0.79–4.12]	1.12 [1.01–2.53]	*P* = 0.89	*P* = 0.65
IL-10 *(pg/mL)*	1.20 [0.38–1.58]	1.42 [0.44–1.78]	*P* < 0.05	0.70 [0.39–1.67]	0.64 [0.33–181]	*P* = 0.59	*P* = 0.74
IL-22 *(pg/mL)*	1.16 [0.60–1.97]	0.94 [0.50–1.27]	***P* = 0.002**	1.10 [0.43–1.34]	0.95 [0.56–1.08]	*P* = 0.68	*P* = 0.38
IL-23 *(pg/mL)*	7.54 [6.82–8.54]	7.38 [6.63–8.82]	*P* = 0.68	*NA*	*NA*	*NA*	*NA*
TNFα *(pg/mL)*	2.08 [1.33–2.53]	1.51 [0.64–2.00]	***P* < 0.001**	1.54 [1.40–2.29]	0.92 [0.62–3.39]	*P* = 0.77	*P* = 0.39
INF-γ *(pg/mL)*	19.66 [9.66–40.11]	17.20 [6.59–32.03]	*P* = 0.32	8.39 [4.31–22.23]	8.45 [2.96–16.99]	*P* = 0.77	*P* < 0.05
R-SH *(uM)*	238.23 [191.64–274.66]	244.63 [206.05–299.12]	*P* = 0.11	216.77 [157.33–279.09]	218.01 [180.01–282.46]	*P* = 0.59	*P* = 0.45
FCP *(mg/kg) ‡*	1170.00 [276.25–2245.00]	120.00 [40.00–221.25]	*P* < 0.05	740.00 [625.00–1650.00]	*NA*	*NA*	*P* = 0.70
Hypoxia-associated parameters							
EPO *(pg/mL)*	83.87 [50.75–137.68]	64.16 [48.32–114.10]	***P* < 0.01**	99.99 [64.00–206.10]	97.86 [40.38–145.01]	*P* = 0.44	*P* = 0.30
MIP-3α *(pg/mL)*	18.60 [10.55–30.79]	13.98 [8.77–20.84]	***P* < 0.01**	19.36 [12.00–21.62]	17.50 [12.97–21.62]	*P* = 0.48	*P* = 0.64
VEGF-A *(pg/mL)*	120.09 [67.45–220.09]	109.18 [61.80–168.87]	*P* = 0.06	85.92 [60.60–233.52]	55.64 [47.45–237.14]	*P* = 0.09	*P* = 0.53
Other parameters							
MCV *(fL)*	89.65 [85.28–93.08]	90.30 [86.00–93.40]	*P* = 0.10	92.20 [88.60–93.60]	89.70 [88.30–93.20]	*P* = 0.95	*P* = 0.34
LDH *(U/L)*	164.00 [134.00–203.00]	168.00 [143.00–199.25]	*P* = 0.16	168.00 [154.00–240.00]	180.50 [143.75–309.75]	*P* = 0.67	*P* = 0.25
Albumin *(g/L)*	41.50 [40.00–44.00]	42.50 [41.00–44.25]	***P* < 0.05**	43.00 [38.50–43.50]	42.00 [39.50–43.50]	*P* = 0.34	*P* = 0.70

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin,

*MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in **bold** represent statistical significance after adjustment for multiple testing.*

Supplementary table 22. Changes in biochemical parameters in patients with IBD stratified by (non-)response to induction therapy with vedolizumab.

	Responders VEDO baseline (n = 33)	Responders VEDO week 6 (n = 33)	Paired analysis	Non-responders VEDO baseline (n = 14)	Non-responders VEDO week 6 (n = 14)	Paired analysis	Baseline difference between groups
Hemoglobin ***(mmol/L)***	**8.10 [7.65–8.95]**	**8.00 [7.70–9.18]**	*P* = 0.29	**7.90 [7.28–8.33]**	**8.00 [7.30–8.25]**	*P* = 0.36	*P* = 0.15
Hemoglobin females	*7.70 [7.50–8.30]*	*7.80 [7.50–8.00]*	*P = 0.65*	*8.10 [7.28–8.43]*	*7.85 [7.35–8.28]*	*P = 0.58*	*P = 0.61*
Hemoglobin males	*8.70 [8.08–9.50]*	*8.90 [8.00–9.50]*	*P = 0.25*	*7.85 [6.83–8.30]*	*8.00 [5.80–8.30]*	*P = 0.60*	*P* < 0.05
Systemic iron status parameters							
Ferritin *(µg/L)*	46.00 [24.00–82.50]	34.00 [23.00–71.50]	*P* < 0.05	31.50 [20.75–135.50]	43.00 [25.00–114.50]	*P* = 0.58	*P* = 0.68
Iron *(µmol/L)*	13.50 [9.55–19.15]	12.90 [8.80–17.70]	*P* = 0.13	8.15 [4.93–11.43]	11.00 [6.35–15.95]	*P* = 0.06	*P* < 0.01
Transferrin *(g/L)*	2.40 [2.20–2.65]	2.50 [2.40–2.80]	***P* < 0.01**	2.40 [2.20–2.63]	2.40 [2.20–3.10]	*P* = 0.18	*P* = 0.93
TIBC *(µmol/L)*	60.00 [55.00–67.00]	64.00 [60.50–70.50]	***P* < 0.01**	61.00 [56.25–66.75]	60.00 [54.50–78.50]	*P* = 0.37	*P* = 0.99
TSAT *(%)*	20.00 [15.00–31.50]	19.00 [13.00–28.00]	*P* = 0.06	13.50 [8.00–18.50]	23.00 [9.50–27.50]	*P* = 0.08	*P* < 0.01
Hepcidin *(ng/mL)*	13.01 [3.88–21.55]	11.87 [5.43–26.26]	*P* = 0.56	11.02 [2.61–29.53]	12.11 [6.06–24.47]	*P* = 0.25	*P* = 0.91
sTfR *(µg/mL)*	7.13 [5.32–10.03]	8.59 [6.70–10.63]	***P* < 0.01**	7.08 [6.02–9.07]	8.07 [6.16–9.32]	*P* = 0.07	*P* = 0.96
sTfR/log Ferritin Index	4.39 [2.99–6.63]	5.36 [3.57–7.48]	***P* < 0.01**	4.76 [3.47–5.10]	4.94 [3.45–6.97]	*P* = 0.06	*P* = 0.87
Inflammation-associated parameters							
CRP *(mg/L)*	2.30 [0.90–4.20]	2.20 [1.20–4.65]	*P* = 0.85	5.10 [2.63–17.50]	9.60 [3.20–16.00]	*P* = 0.78	*P* < 0.05
ESR *(mm/hour)*	13.00 [6.00–27.00]	13.50 [7.00–30.75]	*P* = 0.38	26.00 [8.00–43.75]	32.00 [13.00–37.00]	*P* = 0.62	*P* = 0.26
WBC *(x 10^9/L)*	8.00 [5.70–10.55]	6.70 [5.50–8.10]	*P* < 0.05	7.80 [6.15–12.13]	7.30 [6.05–10.35]	*P* = 0.35	*P* = 0.50
Neutrophils *(x 10^9/L)*	4.99 [3.67–8.63]	4.31 [3.42–5.21]	***P* < 0.01**	5.54 [3.79–8.97]	5.06 [2.98–7.95]	*P* = 0.53	*P* = 0.87
Platelets *(x 10^9/L)*	265.50 [220.00–333.75]	271.50 [227.75–300.50]	*P* = 0.72	355.50 [288.50–374.25]	337.00 [266.00–422.50]	*P* = 0.53	*P* < 0.05
cFGF-23 *(pmol/L)*	0.76 [0.48–1.19]	1.03 [0.47–1.49]	*P* = 0.46	0.84 [0.35–2.14]	1.15 [0.33–1.54]	*P* = 0.86	*P* = 0.53
iFGF-23 *(pg/mL)*	10.12 [7.70–14.71]	10.14 [8.09–13.73]	*P* = 0.74	10.09 [7.97–13.24]	8.92 [7.67–11.00]	*P* = 0.46	*P* = 0.85
c/iFGF-23 ratio	0.06 [0.04–0.11]	0.08 [0.04–0.14]	*P* = 0.97	0.07 [0.04–0.19]	0.07 [0.04–0.17]	*P* = 0.65	*P* = 0.64
IL-1β *(pg/mL)*	0.46 [0.12–1.04]	0.91 [0.26–1.34]	*P* = 0.43	1.00 [0.17–1.15]	1.04 [0.44–1.32]	*P* = 0.31	*P* = 0.54
IL-6 *(pg/mL)*	1.71 [0.91–3.85]	1.82 [1.21–2.88]	*P* = 0.78	3.61 [1.53–6.59]	3.72 [2.21–4.67]	*P* = 0.94	*P* = 0.06
IL-10 *(pg/mL)*	0.93 [0.59–1.57]	0.83 [0.53–1.63]	*P* = 0.43	0.94 [0.55–1.47]	1.20 [0.62–1.55]	*P* = 0.12	*P* = 0.84
IL-22 *(pg/mL)*	1.15 [0.76–1.73]	0.85 [0.66–1.54]	*P* < 0.05	1.69 [0.86–3.12]	1.38 [0.89–2.39]	*P* = 0.15	*P* = 0.31
IL-23 *(pg/mL)*	0.89 [0.42–7.21]	1.18 [0.29–7.27]	*P* = 0.88	6.00 [0.98–8.90]	7.91 [0.19–8.88]	*P* = 0.75	*P* = 0.09
TNFα *(pg/mL)*	1.95 [1.65–2.61]	2.08 [1.74–3.30]	*P* = 0.14	2.97 [2.02–4.34]	3.01 [2.01–4.89]	*P* = 0.97	*P* < 0.05
INF-γ *(pg/mL)*	15.55 [7.73–26.67]	13.75 [7.51–28.19]	*P* = 0.37	19.48 [10.76–68.76]	24.63 [13.68–59.12]	*P* = 0.75	*P* = 0.29
R-SH *(uM)*	216.68 [200.78–271.40]	236.64 [196.55–287.02]	*P* = 0.14	229.99 [185.35–246.72]	212.86 [173.09–220.41]	*P* = 0.06	*P* = 0.49
FCP *(mg/kg) ‡*	410.00 [235.00–1306.00]	115.00 [41.00–217.00]	***P* < 0.01**	880.00 [442.00–2880.00]	1500.00 [482.50–2647.50]	*P* = 0.50	*P* = 0.14
Hypoxia-associated parameters							
EPO *(pg/mL)*	83.98 [49.34–133.25]	74.32 [64.06–128.28]	*P* = 0.94	62.72 [48.09–79.14]	87.48 [58.78–100.55]	*P* < 0.01	*P* = 0.13
MIP-3α *(pg/mL)*	19.23 [10.53–31.96]	22.10 [11.49–36.19]	*P* = 0.89	27.23 [20.67–38.09]	17.77 [12.73–150.55]	*P* = 1.00	*P* = 0.06
VEGF-A *(pg/mL)*	115.60 [74.03–157.80]	120.24 [73.57–217.59]	*P* = 0.71	143.06 [91.21–228.91]	119.60 [94.67–212.83]	*P* = 0.46	*P* = 0.33
Other parameters							
MCV *(fL)*	91.10 [87.13–95.65]	90.25 [88.18–95.23]	*P* = 0.39	89.25 [82.10–92.15]	87.30 [82.75–93.80]	*P* = 0.55	*P* = 0.07
LDH *(U/L)*	181.00 [159.00–227.00]	200.50 [166.50–249.25]	*P* = 0.25	154.00 [138.50–344.00]	157.00 [126.00–261.50]	*P* = 0.21	*P* = 0.32
Albumin *(g/L)*	41.50 [40.00–43.00]	43.00 [40.00–44.00]	*P* = 0.14	39.00 [37.50–42.25]	41.00 [37.50–42.00]	*P* = 0.97	*P* < 0.05

Data are presented as means ± standard deviation (SD) or median [interquartile ranges]. MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, TIBC: total iron-binding capacity, TSAT: transferrin saturation, LDH: lactate dehydrogenase, FCP: fecal calprotectin, cFGF-23: c-terminal Fibroblast Growth Factor 23, iFGF-23: intact Fibroblast Growth Factor 23, sTfR: soluble Transferrin Receptor, IL-1β: interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, EPO: erythropoietin,

MIP-3α: Macrophage Inflammatory Protein 3α, VEGF-A: Vascular Endothelial Growth Factor A, R-SH: free thiols, NA: denotes a variable with too few data points for statistical testing. ‡: FCP measured before and after the induction therapy. P-values presented in ***bold*** *represent statistical significance after adjustment for multiple testing.*

Supplementary table 23. Predictors for response to induction therapy with either infliximab or vedolizumab in patients with IBD.

	RESPONSE TO INDUCTION IN THE IBD GROUP			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	1.88 [0.73–4.85]	0.20		
Age	0.97 [0.94–1.00]	0.08		
BMI	1.00 [0.92–1.08]	0.95		
Disease duration	1.01 [0.97–1.06]	0.66		
Biologicals naïve	2.66 [1.03–6.91]	< **0.05**	4.164 [1.433–12.094]	< **0.01**
Anemia	0.21 [0.08–0.59]	< **0.01**	0.147 [0.048–0.446]	< **0.01**
Iron deficiency	1.68 [0.61–4.67]	0.32		
Iron deficiency anemia	0.40 [0.16–1.02]	0.05		
Inflammation				
Log_2 FCP	0.84 [0.60–1.19]	0.33		
Log_2 ESR	0.72 [0.51–1.02]	0.06		
Log_2 CRP	0.79 [0.62–1.01]	0.07		
Log_2 WBC	0.56 [0.24–1.31]	0.18		
Log_2 Neutrophils	0.73 [0.37–1.44]	0.36		
Log_2 Platelets	0.42 [0.12–1.41]	0.16		
Log_2 Free thiols	1.84 [0.56–6.03]	0.31		
Log_2 IL-1β	0.99 [0.72–1.37]	0.95		
Log_2 IL-6	0.95 [0.71–1.27]	0.71		
Log_2 IL-10	0.92 [0.64–1.31]	0.64		
Log_2 IL-22	0.88 [0.61–1.26]	0.48		
Log_2 IL-23	0.89 [0.64–1.24]	0.48		
Log_2 TNFα	0.63 [0.36–1.09]	0.10		
Log_2 INFγ	1.06 [0.82–1.39]	0.65		
Iron status				
Log_2 Hepcidin	1.11 [0.87–1.42]	0.39		
Log_2 Iron	1.93 [1.08–3.45]	< **0.05**		
Log_2 Ferritin	1.07 [0.75–1.51]	0.71		
Log_2 Transferrin	1.42 [0.22–9.23]	0.71		
Log_2 TIBC	1.19 [0.20–7.07]	0.85		
Log_2 TSAT	1.84 [1.05–3.24]	< **0.05**		
Hypoxia and erythropoiesis				
Log_2 EPO	1.07 [0.68–1.70]	0.76		
Log_2 VEGF-A	0.99 [0.64–1.52]	0.95		
Log_2 MIP-3α	0.76 [0.55–1.06]	0.11		
Log_2 sTfR	0.81 [0.35–1.89]	0.63		
Log_2 sTfR/log Ferritin index	0.82 [0.44–1.51]	0.52		
Log_2 cFGF 23	0.72 [0.48–1.06]	0.10		
Log_2 iFGF 23	0.96 [0.62–1.48]	0.85		
Log_2 c/iFGF ratio	0.84 [0.63–1.11]	0.22		
Other parameters				
MCV	1.05 [0.97–1.14]	0.22		
Log_2 LDH	0.64 [0.24–1.74]	0.38		
Albumin	1.14 [0.99–1.31]	0.07		
Hemoglobin	1.77 [1.01–3.10]	< **0.05**		

For log_2 transformed variables Odds Ratio (OR) represents the increase or decrease in the odds of responding to induction therapy if the value of the variable doubles. FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.

Supplementary table 24. Predictors for response to induction therapy with either infliximab or vedolizumab in patients with Crohn's Disease.

	RESPONSE TO INDUCTION IN THE CD GROUP			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	1.60 [0.41–6.23]	0.50		
Age	0.96 [0.91–1.00]	0.07		
BMI	1.03 [0.91–1.17]	0.61		
Disease duration	1.00 [0.95–1.05]	0.99		
Biologicals naïve	7.56 [1.45–39.40]	< **0.05**	15.86 [2.43–103.57]	< **0.01**
Anemia	0.08 [0.01–0.66]	< **0.05**	0.04 [0.004–0.38]	< **0.01**
Iron deficiency	1.80 [0.39–8.22]	0.45		
Iron-deficiency anemia	0.35 [0.09–1.41]	0.14		
Inflammation				
Log_2 FCP	0.94 [0.60–1.47]	0.78		
Log_2 ESR	0.50 [0.27–0.91]	< **0.05**		
Log_2 CRP	0.65 [0.43–0.98]	< **0.05**		
Log_2 WBC	0.24 [0.05–1.04]	0.06		
Log_2 Neutrophils	0.36 [0.12–1.14]	0.08		
Log_2 Platelets	0.20 [0.03–1.22]	0.08		
Log_2 Free thiols	0.80 [0.14–4.46]	0.80		
Log_2 IL-1β	1.02 [0.59–1.79]	0.94		
Log_2 IL-6	1.10 [0.72–1.69]	0.66		
Log_2 IL-10	1.15 [0.64–2.08]	0.63		
Log_2 IL-22	0.62 [0.37–1.04]	0.07		
Log_2 IL-23	1.10 [0.73–1.46]	0.65		
Log_2 TNFα	1.01 [0.37–2.78]	0.98		
Log_2 INF-γ	0.91 [0.63–1.31]	0.61		
Iron status				
Log_2 Hepcidin	1.08 [0.75–1.55]	0.68		
Log_2 Iron	2.93 [1.23–6.97]	< **0.05**		
Log_2 Ferritin	1.03 [0.63–1.69]	0.90		
Log_2 Transferrin	0.64 [0.05–7.96]	0.73		
Log_2 TIBC	0.61 [0.05–7.18]	0.70		
Log_2 TSAT	3.15 [1.29–7.70]	< **0.05**		
Hypoxia and erythropoiesis				
Log_2 EPO	0.86 [0.41–1.80]	0.68		
Log_2 VEGF-A	1.19 [0.64–2.21]	0.58		
Log_2 MIP-3α	0.97 [0.60–1.57]	0.91		
Log_2 sTfR	0.52 [0.12–2.30]	0.39		
Log_2 sTfR/log Ferritin index	0.71 [0.28–1.83]	0.48		
Log_2 cFGF 23	0.64 [0.35–1.18]	0.16		
Log_2 iFGF 23	0.95 [0.49–1.88]	0.89		
Log_2 c/iFGF ratio	0.82 [0.55–1.21]	0.32		
Other parameters				
MCV	1.00 [0.87–0.99]	0.99		
Log_2 LDH	0.78 [0.19–3.27]	0.73		
Albumin	1.13 [0.93–1.37]	0.22		
Hemoglobin	3.00 [1.14–7.89]	< **0.05**		

For log_2 transformed variables Odds Ratio (OR) represents the increase or decrease in the odds of responding to induction therapy if the variable doubles. 95% CI: 95% confidence interval, FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.

Supplementary table 25. Predictors for response to induction therapy with either infliximab or vedolizumab in patients with ulcerative colitis.

	RESPONSE TO INDUCTION IN THE UC GROUP			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	1.80 [0.42–7.61]	0.43		
Age	0.99 [0.95–1.04]	0.73		
BMI	0.97 [0.87–1.09]	0.61		
Disease duration	1.03 [0.95–1.11]	0.54		
Biologicals naïve	1.17 [0.33–4.09]	0.81		
Anemia	0.30 [0.08–1.10]	0.07		
Iron deficiency	1.53 [0.38–6.16]	0.55		
Iron-deficiency anemia	0.39 [0.11–1.43]	0.16		
Inflammation				
Log_2 FCP	0.74 [0.43–1.28]	0.28		
Log_2 ESR	0.88 [0.56–1.38]	0.57		
Log_2 CRP	0.85 [0.59–1.21]	0.36		
Log_2 WBC	0.93 [0.30–2.88]	0.90		
Log_2 Neutrophils	1.16 [0.46–2.90]	0.76		
Log_2 Platelets	0.57 [0.07–4.57]	0.60		
Log_2 Free thiols	4.06 [0.59–27.73]	0.15		
Log_2 IL-1β	0.86 [0.55–1.34]	0.50		
Log_2 IL-6	0.83 [0.56–1.23]	0.36		
Log_2 IL-10	0.85 [0.55–1.33]	0.49		
Log_2 IL-22	1.39 [0.78–2.50]	0.27		
Log_2 IL-23	0.69 [0.43–1.11]	0.12		
Log_2 TNFα	0.51 [0.25–1.04]	0.07		
Log_2 INF-γ	1.35 [0.83–2.20]	0.22		
Iron status				
Log_2 Hepcidin	1.09 [0.78–1.54]	0.62		
Log_2 Iron	1.58 [0.63–3.97]	0.33		
Log_2 Ferritin	1.13 [0.68–1.87]	0.65		
Log_2 Transferrin	3.53 [0.17–73.55]	0.42		
Log_2 TIBC	2.26 [0.14–36.11]	0.56		
Log_2 TSAT	1.32 [0.56–3.11]	0.53		
Hypoxia and erythropoiesis				
Log_2 EPO	1.35 [0.69–2.66]	0.38		
Log_2 VEGF-A	0.80 [0.42–1.51]	0.48		
Log_2 MIP-3α	0.54 [0.30–0.97]	**< 0.05**		
Log_2 sTfR	1.11 [0.38–3.19]	0.85		
Log_2 sTfR/log Ferritin index	0.93 [0.41–2.11]	0.87		
Log_2 cFGF 23	0.78 [0.46–1.30]	0.34		
Log_2 iFGF 23	1.00 [0.57–1.75]	0.99		
Log_2 c/iFGF ratio	0.84 [0.56–1.25]	0.39		
Other parameters				
MCV	1.13 [0.99–1.26]	0.09		
Log_2 LDH	0.61 [0.14–2.71]	0.51		
Albumin	1.16 [0.94–1.43]	0.17		
Hemoglobin	1.33 [0.65–2.72]	0.44		

For log_2 transformed variables Odds Ratio (OR) represents the increase or decrease in the odds of responding to induction therapy if the variable doubles. 95% CI: 95% confidence interval, FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.

Supplementary table 26. Predictors for response to induction therapy with infliximab in patients with IBD.

	RESPONSE TO INDUCTION IN THE INFLIXIMAB GROUP			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	3.88 [0.74–20.23]	0.11		
Age	0.93 [0.88–0.98]	**< 0.01**	0.92 [0.87–0.98]	**< 0.01**
BMI	0.97 [0.87–1.09]	0.62		
Disease duration	1.01 [0.95–1.07]	0.85		
Biologicals naïve	1.96 [0.43–8.99]	0.39		
Anemia	0.11 [0.01–0.93]	**< 0.05**	0.07 [0.01–0.68]	**< 0.05**
Iron deficiency	1.61 [0.36–7.28]	0.54		
Iron-deficiency anemia	0.48 [0.12–1.96]	0.30		
Inflammation				
Log_2 FCP	1.02 [0.59–1.78]	0.94		
Log_2 ESR	0.59 [0.33–1.06]	0.08		
Log_2 CRP	0.89 [0.61–1.30]	0.53		
Log_2 WBC	0.49 [0.11–2.12]	0.34		
Log_2 Neutrophils	0.45 [0.14–1.47]	0.18		
Log_2 Platelets	1.13 [0.19–6.68]	0.89		
Log_2 Free thiols	1.75 [0.33–9.31]	0.51		
Log_2 IL-1β	0.65 [0.21–2.07]	0.47		
Log_2 IL-6	1.05 [0.68–1.61]	0.82		
Log_2 IL-10	1.12 [0.64–1.94]	0.70		
Log_2 IL-22	1.21 [0.73–2.01]	0.45		
Log_2 IL-23	0.89 [0.28–2.82]	0.84		
Log_2 TNFα	1.27 [0.53–3.06]	0.59		
Log_2 INF-γ	1.44 [0.96–2.18]	0.08		
Iron status				
Log_2 Hepcidin	1.16 [0.81–1.66]	0.42		
Log_2 Iron	1.00 [0.44–2.27]	1.00		
Log_2 Ferritin	1.10 [0.66–1.85]	0.71		
Log_2 Transferrin	1.28 [0.08–21.69]	0.87		
Log_2 TIBC	1.20 [0.09–16.44]	0.89		
Log_2 TSAT	0.99 [0.44–2.26]	0.99		
Hypoxia and erythropoiesis				
Log_2 EPO	0.58 [0.27–1.27]	0.17		
Log_2 VEGF-A	1.19 [0.63–2.27]	0.59		
Log_2 MIP-3α	1.05 [0.64–1.73]	0.84		
Log_2 sTfR	0.41 [0.11–1.49]	0.17		
Log_2 sTfR/log Ferritin index	0.58 [0.24–1.39]	0.22		
Log_2 cFGF 23	0.51 [0.27–0.96]	**< 0.05**		
Log_2 iFGF 23	0.94 [0.51–1.71]	0.83		
Log_2 c/iFGF ratio	0.74 [0.50–1.10]	0.13		
Other parameters				
MCV	0.96 [0.85–1.09]	0.52		
Log_2 LDH	0.50 [0.11–2.21]	0.36		
Albumin	1.05 [0.86–1.27]	0.65		
Hemoglobin	2.16 [0.86–5.39]	0.10		

For log_2 transformed variables Odds Ratio (OR) represents the increase or decrease in the odds of responding to induction therapy if the variable doubles. 95% CI: 95% confidence interval, FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.

Supplementary table 27. Predictors for response to induction therapy with vedolizumab in patients with IBD.

	RESPONSE TO INDUCTION IN THE VEDOLIZUMAB GROUP			
	Univariable OR (95% CI)	***P*-value**	**Multivariable OR (95% CI)**	***P*-value**
Gender (reference male)	1.11 [0.32–3.92]	0.87		
Age	1.02 [0.97–1.06]	0.53		
BMI	1.03 [0.91–1.16]	0.68		
Disease duration	1.02 [0.94–1.10]	0.70		
Biologicals naïve	1.62 [0.29–8.97]	0.58		
Anemia	0.15 [0.04–0.59]	**< 0.01**		
Iron deficiency	2.24 [0.50–10.04]	0.29		
Iron-deficiency anemia	0.22 [0.06–0.88]	**< 0.05**		
Inflammation				
Log_2 FCP	0.74[0.46–1.18]	0.21		
Log_2 ESR	0.77 [0.49–1.23]	0.27		
Log_2 CRP	0.63 [0.43–0.93]	**< 0.05**		
Log_2 WBC	0.68 [0.24–1.93]	0.46		
Log_2 Neutrophils	1.04 [0.44–2.48]	0.93		
Log_2 Platelets	0.08 [0.01–0.66]	**< 0.05**		
Log_2 Free thiols	1.78 [0.28–11.39]	0.54		
Log_2 IL-1β	0.89 [0.57–1.39]	0.62		
Log_2 IL-6	0.87 [0.56–1.33]	0.51		
Log_2 IL-10	0.85 [0.52–1.39]	0.52		
Log_2 IL-22	0.62 [0.33–1.16]	0.13		
Log_2 IL-23	0.72 [0.49–1.08]	0.11		
Log_2 TNFα	0.46 [0.21–1.02]	0.06		
Log_2 INF-γ	0.87 [0.61–1.24]	0.43		
Iron status				
Log_2 Hepcidin	1.03 [0.73–1.45]	0.86		
Log_2 Iron	5.59 [1.72–18.18]	**< 0.01**	6.41 [1.49–27.71]	**< 0.05**
Log_2 Ferritin	1.03 [0.63–1.70]	0.90		
Log_2 Transferrin	1.33 [0.09–19.31]	0.83		
Log_2 TIBC	1.12 [0.08–15.19]	0.93		
Log_2 TSAT	4.81 [1.56–14.81]	**< 0.01**		
Hypoxia and erythropoiesis				
Log_2 EPO	1.68 [0.76–3.68]	0.20		
Log_2 VEGF-A	0.80 [0.41–1.56]	0.52		
Log_2 MIP-3α	0.52 [0.28–0.98]	**< 0.05**	0.41 [0.17–0.97]	**< 0.05**
Log_2 sTfR	1.11 [0.34–3.58]	0.86		
Log_2 sTfR/log Ferritin index	0.98 [0.40–2.94]	0.96		
Log_2 cFGF 23	0.82 [0.46–1.46]	0.49		
Log_2 iFGF 23	1.26 [0.56–2.84]	0.57		
Log_2 c/iFGF ratio	0.81 [0.51–1.29]	0.37		
Other parameters				
MCV	1.15 [1.01–1.31]	**< 0.05**		
Log_2 LDH	1.02 [0.25–4.18]	0.98		
Albumin	1.28 [1.00–1.63]	**< 0.05**		
Hemoglobin	1.79 [0.85–3.77]	0.13		

For log_2 transformed variables Odds Ratio (OR) represents the increase or decrease in the odds of responding to induction therapy if the variable doubles. 95% CI: 95% confidence interval, FCP: fecal calprotectin, MCV: Mean Corpuscular Volume, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive protein, WBC: white blood cell count, LDH: lactate dehydrogenase, IL-1β: Interleukin 1β, IL-6: Interleukin 6, IL-10: Interleukin 10, IL-22: Interleukin 22, IL-23: Interleukin 23, TNFα: Tumor Necrosis Factor α, INF-γ: Interferon γ, TIBC: total iron-binding capacity, TSAT: transferrin saturation, EPO: erythropoietin, VEGF-A: Vascular Endothelial Growth Factor A, MIP-3α: Macrophage Inflammatory Protein 3α, sTfR: soluble Transferrin Receptor, cFGF 23: c-terminal Fibroblast Growth Factor 23, iFGF 23: intact Fibroblast Growth Factor 23.